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Abstract 
Background: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a 
complex condition associated with multiple symptoms, everyday functional impairment and 
reduced quality of life. However, there is a paucity of published literature on the symptoms 
associated with everyday functional impairment and quality of life of adults in Australia with 
ME/CFS. In particular, use of psychometrically tested, disease specific measurement tools is 
limited. This has implications for understanding the unique symptom presentation of 
ME/CFS and appropriate clinical management.  
Aim: To explore the association between symptoms, everyday function and quality of life in 
a cohort of adult Australians with ME/CFS.  
Objectives: 1) To describe participants demographic characteristics 2) To explore symptoms 
(using the ME/CFS specific DePaul Symptom Questionnaire (DSQv1) and their association 
with everyday function and quality of life (using the generic Medical Outcomes 36-item 
Short Form Health Survey (SF-36) in adults who meet the Institute of Medicine clinical 
diagnostic criteria for ME/CFS.  
Method: A cross-sectional sample was obtained from respondents to advertisements on 
social media, support organisation websites and newsletters. Descriptive statistics were 
obtained on demographics, symptom scores and everyday function and quality of life. 
Symptom domains were created from the DSQv1. Associations between symptom domains, 
everyday function and quality of life were examined using Spearman’s correlations.  
Results: One hundred and fifty-six respondents met the Institute of Medicines clinical 
diagnostic criteria. The majority of respondents were female (88.5%) and highly educated. In 
all, 51 (32.7%) were in paid employment and 105 (67.3%) were not in paid employment.  
All symptom domains had a significant, negative association with the Physical Component 
Summary of the SF-36 at the p = 0.01 level. The symptom domains with the strongest 
negative association were post-exertional malaise (Rs = -.596), fatigue (Rs -.539) and pain 
(Rs = -.506).  
Conclusion: This Australian study found that post-exertional malaise, fatigue and pain have 
a strong negative association with everyday function and quality of life in adults with 
ME/CFS. These findings support local and international literature on the importance of multi-
symptomatic management of ME/CFS. It also supports investigating the everyday functional 
limitations of patients and how they perceive their QoL to develop better measurement tools 
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and instigate appropriate supports. Due to the high levels of unemployment in this study, the 
health economic implications of ME/CFS are of high priority for further study.  
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List of terms and abbreviations  
ME Myalgic Encephalomyelitis, an earlier term often combined with Chronic Fatigue 
Syndrome 
 
CFS Chronic Fatigue Syndrome, a term developed by the Centers for Disease Control 
 
ME/CFS Myalgic encephalomyelitis/Chronic Fatigue Syndrome. Acronym chosen for the thesis 
both for brevity and reflective of current usage.. 
 
pwME People with Myalgic Encephalomyelitis/Chronic fatigue syndrome. Standard 
abbreviation in the psychology literature to refer to people with a particular condition, for 
example with people with Multiple Sclerosis (pwMS).  
 
Fukuda Diagnostic criteria developed by the Centres for Disease Control 
 
CCC Canadian Consensus Criteria 2003 developed by expert consensus 
 
ICC International Consensus Criteria 2011, further extension of the CCC 
 
IOM criteria The most recent criteria developed by the Institute of Medicine after an extensive 
literature review. Also called “systemic exertion intolerance disease” originally although 
this name has not gained traction 
 
DSQv1 Version one of the DePaul Symptom Questionnaire 
 
SF-36 Medical Outcomes 36-item Short Form Health Survey 
 
PCS Physical Component Summary of the SF-36 
 
MCS Mental Component Summary of the SF-36 
 
PEM Post-Exertional Malaise, symptom related to physiological abnormalities of normal 
exertion and varies between pwME. A disease specific symptom.  
 
Function Used by the World Health Organisation to refer to body functions, body structures, 
activities and participation in the context in which the person lives.  
 
Psychometric The psychometric properties of a measurement instrument refer to how reliable and valid 
the instrument is in measuring what it sets out to measure e.g fatigue, mental health, 
physical function  
 
QoL  Quality of Life. How people feel about their health condition or its consequences; hence 
it is a construct of “subjective well-being”  
 
CPET Cardio Pulmonary Exercise Test 
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Chapter 1 Introduction  
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1.1 Overview  
Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome (ME/CFS) is a complex, multi-
symptomatic condition that involves multiple body systems (McGregor et al. 2019). A 
diagnosis of ME/CFS according to the recent Institute of Medicine (IOM) clinical criteria 
includes “a substantial reduction or impairment in the ability to engage in pre-illness levels of 
occupational, educational, social or personal activities” (Institute of Medicine (IOM), 2015, 
p6). Hence, ME/CFS is associated with significant reductions in everyday function. 
Furthermore, ME/CFS is often associated with a low quality of life (QoL) (Hvidberg et al. 
2015; Kingdon et al. 2018). This can be defined as how someone feels about their health 
condition or its consequences and is thus a “subjective perception of wellbeing” (World 
Health Organisation (WHO), 2007, p. 267). Use of psychometrically tested self-report 
questionnaires to assess how someone perceives various aspects of their health (such as 
physical and psychological function) is thus a useful measure of individual health outcomes 
(Ware and Sherborne, 1992). Moreover, this approach has been shown to 
reliably complement commonly used clinical data in practice (Hahn et al. 2007). On a 
broader policy level, such assessments allow for better evaluation of current services, 
allocation of funding and service design (Hand, 2016).  
Despite ME/CFS being a multi-symptomatic condition, there is a paucity of literature on the 
symptoms most associated with poor everyday function and QoL within the Australian 
population using psychometrically tested assessment tools. This is important because people 
with ME/CFS (pwME) often report problems with obtaining a diagnosis, negative health care 
encounters, and stigma relating to the severity of their reported symptoms or reductions in 
everyday function (Anderson et al. 2012; McManimen et al. 2018). Although the literature 
that has identified these factors is largely international, these problems are evident within the 
Australian health care system. A recent report to the Chief Executive Officer of the National 
Health and Medical Research Council (National Health and Medical Research Council 
(NHMRC) 2019) highlighted the difficulty people pwME have in Australia accessing 
government administered support or appropriate health care. In the public consultation for the 
report, patients, researchers and health care providers identified delays in diagnosis, stigma 
and inappropriate symptom management experienced by patients as significant issues. Hence 
increasing the knowledge base regarding the association between symptoms and everyday 
function may improve health care for pwME by 1) increasing health care practitioners 
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knowledge of the symptoms most in need of management and 2) fostering understanding of 
the significant reductions in everyday function and QoL (Friedman et al. 2019).   
1.2 Research question  
The original working question was “Is there one symptom that has the strongest association 
with everyday functional impairment and QoL in ME/CFS”. For example, fatigue is a 
symptom that has strong associations with ME/CFS. However, after a review of the literature 
it was clear that there are many symptoms that may be associated with reduction in everyday 
function and QoL hence the final question was:  
 “Which symptoms are associated with everyday functional impairment and reduced QoL in 
ME/CFS?”.  
In addition to answering the specific research question, the demographic characteristics of the 
participants is explored in order to understand the specific ME/CFS population captured such 
as gender distribution, education and employment.  
1.3 Data 
The data for this thesis comes from a larger research project on ME/CFS. The process for this 
thesis involved two elements: 1) assisting with recruitment for the larger study 2) formulation 
of a research question from the literature review to apply to a portion of that data and 3) 
analysis of data.  
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Chapter 2 Literature review 
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2.1 Introduction 
There is currently no consensus on the diagnostic criteria to apply to a patient presenting with 
symptoms of ME/CFS in clinical practice or to apply within a research setting (IOM, 2015). 
One systematic review counted twenty proposed criteria (Brurberg et al. 2014) with a further 
simplified clinical diagnostic criteria introduced by the IOM in 2015 (IOM, 2015). This 
situation is compounded by the lack of a clinically acceptable diagnostic 
biomarker (Vanelzakker, Brumfield & Lara Mejia 2019). Furthermore, ME/CFS can present 
in different ways. There are documented epidemics however cases are thought to be largely 
sporadic (Jason et al. 2009a). Symptom presentation may be either rapid or gradual with 
ongoing, shifting symptom patterns (Daniel, Annesley & Fisher 2019). This situation 
complicates research endeavours as it is difficult to compare studies with such heterogenous 
patient cohorts (IOM, 2015). It has also contributed to confusion for health care workers in 
making an accurate diagnosis (NHMRC, 2019). Currently diagnosis relies on identification 
of core features such as a significant reduction in pre illness level of capacity and self-
reported symptoms. These symptoms vary according to diagnostic criteria but usually 
include profound fatigue, cognitive impairment, pain and difficulty with sleep. Specific to 
ME/CFS, there is often a delayed exacerbation of symptoms and protracted recovery to 
baseline after physical, cognitive or emotional exertion, termed post-exertional malaise 
(PEM) (Davenport et al. 2019). 
Measurement of reported symptoms in the literature has been inconsistent and therefore it can 
be difficult to compare studies or develop treatment approaches. Hence, after briefly 
discussing the search strategy used to identify the relevant literature, this chapter will begin 
with an overview of the epidemiology of ME/CFS and some of the associated functional 
limitations associated with the condition. The different approaches to symptoms and their 
management will then be examined via a review of diagnostic criteria and subsequent 
treatment modalities currently offered to patients and the evidence attached to these 
modalities. An examination of two self-report tools to accurately measure symptoms (the 
DSQv1) and everyday function and QoL (SF-36) will be made. A gap in the Australian 
literature that examines the relationship between ME/CFS specific symptoms, functional 
limitations and QoL using these two questionnaires is identified.  
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2.2 Search strategy 
A search of the literature was conducted to identify studies investigating symptoms, 
measurement of symptoms and symptom severity. Searches were conducted in PubMed, 
CINHAL, and PsychINFO using the terms ‘Myalgic Encephalomyelitis’, ‘Chronic 
Fatigue Syndrome’, AND ‘severity’ AND ‘symptoms’ with an additional search on Google 
to identify government reports. The number of articles identified and themes that were 
identified are outlined in Figure 1. From these searches an initial matrix was developed 
(Appendix 1). The matrix is not an exhaustive document of all literature referenced however 
it formed the basis from which the literature review developed. Primary sources included 
both peer reviewed qualitative and quantitative research; studies on biological causes were 
included if they converged with identified themes. Secondary sources included significant 
government reviews and systematic reviews based on primary sources. The focus of this 
review is on adults as there are epidemiological, contextual and phenotypic differences 
between children and adults with ME/CFS (Rowe et al. 2017). It was noted that many studies 
of ME/CFS have not been replicated, hence no date range was specified, and some referenced 
articles are more than ten years old. Articles were limited to English. As themes emerged, an 
iterative process was employed to develop a coherent understanding of the topic and identify 
further areas for knowledge development. 
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Figure 1 Literature search flow chart 
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2.3 Epidemiology 
Reported prevalence estimates of ME/CFS vary widely and range from 0.03% to 6.41% 
(Carruthers et al. 2012; Lloyd et al. 1990; Nacul et al. 2011). Higher prevalence estimates 
occur with self-report data compared to clinically confirmed cases (Johnston et al. 2013) or 
with use of broad diagnostic criteria which may include people with unspecified fatigue, as 
opposed to ME/CFS (Baraniuk 2017; Jason et al. 2009b). This highlights one of the 
inconsistencies in the literature and challenges for identifying similar cohorts for biologic 
research or needs assessment and service design. The only Australian point prevalence study 
(Lloyd et al. 1990) found a low prevalence of 0.03% across a broad demographic population 
using case identification criteria developed by the researchers rather than an international 
standard. By contrast a meta-analysis (Johnston et al. 2013) found an international pooled 
prevalence of 0.87% (95% CI: 0.23-1.29) based on clinically assessed samples. The meta-
analysis was of cases according to a criterion developed by the Centers for Disease Control, 
the Fukuda criteria (Fukuda et el. 1994) which has been the most utilised criteria (IOM, 
2015). This estimate needs to be interpreted with caution as there are indications ME/CFS is 
underdiagnosed with community based population studies suggesting up to 90% of people 
with pwME may not be diagnosed (Jason et al. 1999; Reyes et al. 2003). Although true 
population prevalence studies are approximately twenty years old more recent qualitative 
studies indicate general practitioners are often unwilling to make a diagnosis (Bayliss et al. 
2014) suggesting rates of diagnosis may remain low.  
The reported ratio of males to females with ME/CFS in the literature is generally 1:4 (IOM 
2015). However a recent study in the United States using large scale medical claims data 
found 40% of those diagnosed were men (Valdez et al. 2019). It is not clear what is causing 
this discrepancy but one possible explanation is that the large scale data mining techniques 
used by Valdez et al. (2019) were able to capture a better estimate of prevalence in men and 
women. This requires further investigation as it is in contrast to a large community-based 
population prevalence study by Jason et al. (1999, p. 2135) where 522 women and 291 men 
were affected per 100 000. ME/CFS can occur at any age however two peaks for age of onset 
have been described; one from 10 -19 years (Bakken et al. 2014) and the second between 25 
– 35 years of age (Jason et al. 1999) thus affecting people at critical educational and 
employment periods of their lives (Collin et al. 2011; Rowe et al. 2017). 
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2.4 Everyday functional impairment  
Despite the known significant reduction in everyday function, there is no agreed severity tool 
for clinicians to determine this assessment (Hardcastle et al. 2016; Strassheim et al. 2017). 
According to one clinical primer which provides information for clinicians managing pwME 
(Carruthers et al. 2012), a person with mild ME/CFS will likely remain employed and 
manage Activities of Daily Living (ADLs) with difficulty. A person with moderate 
ME/CFS will have a 50% reduction in activity, restricted mobility and be unable to 
consistently perform ADLs such as cleaning or daily bathing. A person with severe ME/CFS 
is housebound and only able to attend minimal ADLs and will likely require mobility aids 
and a very severe case is dependent on a carer for all functions and may be unable to hold a 
conversation. In a scoping review on severe and very severe ME/CFS, Strassheim et al. 
(2017) found the prevalence of this category of patients to be quoted as ten to twenty five 
percent by patient organisations. However, the true prevalence has not been established due 
to differences in assessment of severity and difficulties accessing this group of pwME due to 
the severity of their condition. 
Currently it is thought that recovery from ME/CFS is low and definitions of recovery are 
inconsistent (IOM, 2015). Of particular importance, self-reports of recovery appear to be 
unreliable. Brown et al. (2012) reviewed 25 pwME who had been diagnosed approximately 
25 years previously and found 17 out 23 outcomes were not statistically different between 
those who classified themselves as recovered compared to those who reported still having 
ME/CFS. This was a small study however a more recent observational cohort study (n=784) 
also examined symptoms and function experienced by young adults who had been diagnosed 
in adolescence. The study found considerable crossover in functional scores between those 
who defined themselves as recovered and those who did not (Rowe 2019). In a nine-year 
longitudinal study, only two out of 34 participants had recovered; the highest indicator of 
functional impairment (defined as disability) was work status followed by the symptom PEM 
(Andersen, Permin & Albrecht 2008).  
Indeed, one area that exemplifies reduction in function in ME/CFS is work capacity and 
retention (Schafer et al. 2015). An Australian cross-sectional study found 34.2% on a 
disability pension, 26% as unemployed and only 9.7% maintained full time employment. The 
study did not identify if there were particular symptoms with a stronger association with 
reduced work activity (Johnston, Staines & Marshall-Gradisnik 2016). This was explored in a 
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large Spanish community based prospective study (n=1086) (Castro-Marrero et al. 2019) 
where they found the symptoms most associated with unemployment were broad and related 
to muscular, cognitive, neurological, autonomic and immune systems. However in their 
regression model, only autonomic related symptoms predicted work disability. The study did 
not report on return to work rates and a critical review of the literature found that it was not 
possible to provide definitive data on this due to heterogeneity of studies. However the 
indication is return to work rates are low and successful maintenance of employment relies 
on flexible arrangements with lower work hours (Vink & Vink-Niese 2019).  
Qualitative literature not only identifies reductions in function but explores the difficulties 
pwME have in adapting to their limitations. Most notably, there are issues related to the 
health care encounter that may create barriers to better function and QoL. Anderson, Jason 
and Hlavaty (2014) interviewed 19 participants from a larger community based 
epidemiological study and found restructuring of life was required in order to cope with the 
impairments associated with the onset of ME/CFS. Participants identified limited medical, 
social or structural support as factors contributing to difficulties with adjusting to changes in 
circumstances. Likewise, a study of 26 adults with Post Viral Fatigue Syndrome, a term 
which has been equated with ME/CFS, found participants experienced delays in medical 
diagnosis, lack of understanding from health care professionals regarding the impact 
symptoms were having on everyday life and resulting lack of symptomatic management 
(Stormorken, Jason & Kirkevold 2017). It must be noted that both studies (Anderson, Jason 
& Hlavaty 2014; Stormorken, Jason & Kirkevold 2017) rely on recall hence recall bias may 
be a factor in how experiences are interpreted over time and further prospective studies are 
warranted.  
2.5 ME/CFS and stigma 
Experience of stigma is a common theme within the literature and often relates to how 
symptoms are interpreted by others and how they are experienced by pwME. A large cross-
sectional study (n=551) found evidence of a relationship between higher ME/CFS symptom 
severity, experience of stigma and suicidal ideation, both with and without depression in 
adults with ME/CFS (McManimen et al. 2018). One source of stigma sits within the 
individual and structural components of the health care system. A qualitative meta synthesis 
found some general practitioners and practice nurses framed patients as difficult or 
exaggerating the impact of their symptoms (Bayliss et al. 2014). One explanation for this 
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could be that clinicians identify a lack of confidence in managing ME/CFS symptoms due to 
the complexity and controversy over diagnosis and lack of available education or 
management pathways (Anderson et al. 2012; Bayliss et al. 2016). A further contributing 
factor may lie in differences in interpretation of the meaning of symptoms between schools of 
thought and, at times, between patients and health care providers (Bayliss et al. 2014; Chew-
Graham et al. 2011). Hence, development of resources for health care workers requires an 
understanding of the historical and current criteria available to diagnose ME/CFS as these 
exemplify some of the different interpretations attached to presenting symptoms.  
2.6 Historical and current perspectives on diagnosing ME/CFS  
2.6.1 Context for multiple criteria.  
Shifting perceptions and narratives surrounding ME/CFS can be seen in the diagnostic 
criteria that have emerged with different groups developing diagnostic criteria that reflect 
particular interpretations of the literature, including interpretation of prevailing biological 
findings and patient reports of symptoms (Geraghty & Esmail 2016).  
2.6.2 Oxford Criteria 
A behavioural interpretation of presenting symptoms was developed in the 1970’s when a 
group of psychiatrists (McEvedy and Beard, 1970) reviewed the Royal Free epidemic of 
1955, and concluded that these cases were the product of hysteria due to cases being 
predominantly women with no evidence of objective findings (IOM, 2015; McEvedy and 
Beard, 1970).  In the late 1990’s a group of British psychiatrists (Vercoulen et al., 
1998) introduced a slightly different model where any ongoing biological aberrations were 
interpreted as consequences of perpetuating, false or maladaptive beliefs 
and behaviours regarding symptoms (Maes and Twisk, 2010, Sunnquist and Jason, 2018). In 
this model, pwME are encouraged to push through perceived negative symptoms 
in an attempt to re-train the body towards normal physiological function (Davenport et al., 
2010). Associated with this model is the Oxford Criteria (Sharpe et al., 1991). This criteria 
requires: fatigue of six months or longer, reduction in pre illness function and exclusion of 
psychiatric illness (Sharpe et al., 1991). Lack of specificity is a problem with this criteria as 
study participants may not have ME/CFS, but other fatigue causing illnesses such as an 
autoimmune disease or generalised chronic fatigue of unknown origin (Baraniuk 
2017). There is decreasing acceptance of this criteria for studying ME/CFS (IOM, 2015), 
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however studies into treatment modalities based on false belief and behaviours still influence 
treatment guidelines (NHMRC, 2019). 
2.6.3 The problem with unspecified fatigue as a diagnosis of ME/CFS 
Many of the proposed criteria for ME/CFS include the presence of fatigue as an essential 
criterion for diagnosis, with the required duration of fatigue usually being six months or more 
with additional symptoms as discussed below. Whilst fatigue is a prominent and often 
incapacitating symptom in ME/CFS, it is also a common symptom across many disease 
processes, and causes may range from acute viral infection, autoimmune disease, cancer, 
psychiatric illness and medication side effects (Wilson et al., 2014). Fatigue is a subjective 
description that is difficult to quantify in biomedical terms. Weather the fatigue experienced 
by pwME shares similar biological mechanisms to other illnesses with a high fatigue 
component is an outstanding question (Karshikoff, Sundelin & Lasselin 2017). As fatigue is 
difficult to define, health care professionals often struggle to understand the distinct needs of 
the person reporting fatigue (Gielissen et al., 2007). For this reason it is important that the 
language used is descriptive of the fatigue experienced within an individual condition (Jason 
et al. 2009b). For example, there may be separate symptoms or dimensions to fatigue that are 
contributing to an overall reporting of fatigue. For example, cognitive fatigue, sometimes 
referred as “brain fog” by pwME (Carruthers et al. 2012) may reflect issues with memory or 
concentration and is one of the most prevalent reported symptoms (IOM, 2015). Symptoms 
may also fluctuate depending on other factors such as how physically fatigued the person 
may be, or duration of the cognitive task (Attree et al. 2014; Carruthers et al. 2012; Jason et 
al. 2009c). Additionally, other symptoms may contribute to an overall perception of fatigue, 
that may be amenable to treatment and may consequently reduce fatigue. Jones et al. (2011) 
found orthostatic symptoms, anxiety and depression were independent predictors of current 
fatigue. Thus, attenuation of fatigue may be possible with interventions targeted to individual 
symptoms or circumstances that may not appear directly related to fatigue. Hence, 
assessment of the full spectrum of symptoms within ME/CFS is important in establishing 
contributors to fatigue, development of symptom appropriate management and further 
research into biological mechanisms.  
2.6.4 The inclusion of post-exertional malaise 
A recent shift towards a biological interpretation of symptoms has occurred that focuses on 
the unique issues with exertion and energy production in ME/CFS with the term PEM being 
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used to encompass these findings (Holtzman et al. 2019; McGregor et al. 2019). PEM is now 
seen as specific for a diagnosis of ME/CFS (IOM, 2015). PEM has been described as the 
increase in some or all of a persons’ symptoms, such as fatigue, muscle fatigability, pain, 
cognitive issues, autonomic or immunological symptoms post physical, cognitive or 
psychological exertion that is not proportional to that exertion (Arroll et al. 2014; Chu et al. 
2018; Jason et al. 2018a). Although fatigue post exertion is evident in many disease 
processes, such as cancer and multiple sclerosis, the exacerbation of multiple symptom 
domains is likely unique to ME/CFS (Jason & Sunnquist 2018a; McGregor et al. 2019). 
Additionally, the temporal component of PEM is unique and can involve both a delay in 
exacerbation of symptoms and a variable trajectory of recovery to baseline symptom severity 
and function (Chu et al. 2018; McGregor et al. 2019). Self-reported recovery ranges from 24 
hours to months (Chu et al. 2018; Holtzman et al. 2019). Objective measurement of delayed 
exacerbation and recovery has also been examined using sequential, two day 
Cardiopulmonary Exercise Testing (CPET) whereby pwME are unable to reproduce oxygen 
consumption and workload levels at Ventilatory Threshold (VT) on day two indicating a post 
exertional reduction in exercise capacity (Snell et al. 2013). This is not evident in healthy 
sedentary controls or those with cardiovascular disease, lung disease, end stage renal disease 
and cystic fibrosis (Hodges, Nielsen & Baken 2018; Keller, Pryor & Giloteaux 2014; Snell et 
al. 2013). Stevens et al. (2018) further elaborates that VT is not normally reached during 
activities of daily living, however pwME may enter anaerobic levels of activity resulting in 
symptom exacerbation during minor activities. Sequential CPET has been suggested as an 
accurate diagnostic test (Nelson et al. 2019) although it carries high risk to pwME as it is 
unclear how to assess the risk posed to each individual by deliberately triggering PEM 
(Stevens et al. 2018).  
2.6.5 Fukuda criteria, Canadian Consensus Criteria, International Consensus Criteria and 
the Institute of Medicine clinical criteria 
Table 1 sets out the essential and optional symptoms for a diagnosis according to the Fukuda 
criteria (Fukuda et al. 1994), Canadian Consensus Criteria (CCC) (Carruthers et al. 2003), 
International Consensus Criteria (ICC) (Carruthers et al. 2011) and the Institute of Medicine 
clinical criteria (IOM, 2015). A recent review (Blomberg et al. 2018) found more coherent 
pathophysiological findings are evident in studies applying these criteria and, except for the 
Fukuda criteria, PEM is an essential symptom. A number of studies have also found that the 
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CCC and ICC select smaller cohorts with more functional impairment and severe symptoms, 
suggesting specificity (Jason et al. 2016). Although this may have utility in identifying 
biological causation, these criteria may miss those pwME who are less severe in clinical 
contexts and they may be too complex to apply within a standard clinical encounter (IOM, 
2015). The IOM clinical criteria is a simplified criteria for use in a clinical setting and 
captures a wider range of severity (Jason, Sunnquist et al. 2015a). Jason et al (2015b) found 
including orthostatic intolerance in the IOM criteria only increased the percentage of those 
meeting the criteria by two percent. However in terms of clinical utility, orthostatic 
intolerance may be underdiagnosed and it is a symptom amenable to treatment (Reynolds et 
al. 2014). On the other hand, the criteria omits pain, which is a prevalent symptom in 
ME/CFS (Strand et al. 2019). It will remain unclear if these criteria represent distinct clinical 
entities (Twisk 2019) or related subgroups until biological markers are discovered (Daniel, 
Annesley & Fisher 2019). However, the IOM report emphasised that ME/CFS is a diagnosis 
to be made with their simplified diagnostic criteria providing an easy screening tool to use in 
clinical settings (IOM 2015).  
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Table 1. Symptoms according to diagnostic criteria 
Fukuda CFS 1994 
(Fukuda et al. 1994) 
Canadian Consensus 
Criteria ME/CFS 2003 
(Carruthers et al. 2003) 
International Consensus 
Criteria ME 2011 
(Carruthers et al. 2011) 
Institute of Medicine  
(Institute of Medicine 
(IOM) 2015) 
• Prolonged or 
chronic fatigue that 
persists or relapses 
for six months or 
more 
AND 
• Four or more of the 
following 
- Impaired 
memory or 
concentration 
- Sore throat 
- Tender cervical 
or axillary 
lymph nodes 
- Muscle pain 
- Multi-joint pain 
- New headaches 
- Post-exertional 
malaise 
 
• Illness lasting six or 
more months 
• Fatigue 
• Post-exertional 
malaise 
• Sleep dysfunction 
• Pain 
• Two or more 
neurological/cognitive 
manifestations 
AND 
• At least one from two 
of the following 
categories 
- Autonomic 
- Neuroendocrine 
- Immune 
 
• Post-exertional 
neuroimmune 
exhaustion 
• At least one 
symptom from 
three of the 
following 
categories 
- Neurocognitive 
- Pain 
- Sleep 
disturbance 
- Neurosensory, 
perceptual or 
motor 
disturbances 
AND 
• At least one 
symptom from 
three of the 
following 
- Flu like 
symptoms 
- Susceptibility 
to viral 
infections with 
prolonged 
recovery 
periods 
- Gastrointestinal 
tract 
- Genitourinary 
- Food 
sensitivities 
AND 
• At least one 
symptom from the 
following 
- Cardiovascular 
- Respiratory 
- Loss of 
thermostatic 
stability 
- Intolerance of 
extremes of 
temperature 
• Symptoms, 
including fatigue 
that is not lifelong, 
not the result of 
excessive exertion 
and not 
substantially 
alleviated by rest 
have persisted for 
more than six 
months 
AND 
 
• Post exertional 
malaise 
• Unrefreshing sleep 
AND 
• At least one of the 
two symptoms 
- Cognitive 
impairment 
- Orthostatic 
intolerance 
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2.7 Symptom management and treatment options 
2.7.1 Pharmacological treatment 
A number of pharmacological treatments have been explored but have failed at more 
advanced phase trials. A recent example is a randomised double-blind placebo-controlled 
phase three trial of the B-Lymphocyte depletion drug Rituximab in those with a CCC 
diagnosis (Fluge et al. 2019). The trial found no statistically significant difference between 
cases and controls. This was in contrast to a promising phase two trial of the same drug 
(Fluge et al. 2011). A systematic review of pharmacological therapies for ME/CFS found that 
there was inconsistent evidence for any of the therapies assessed (Collatz et al. 2016). The 
review found two major weaknesses in the literature to be lack of standardisation of 
participants according to diagnostic criteria and outcome measures. Hence, pharmacological 
and nutraceutical treatments are currently prescribed based on clinician experience to target 
individual symptoms (Bested & Marshall 2015; Carruthers et al. 2012; Castro-Marrero et al. 
2017; Smith et al. 2014).  
2.7.2 Graded Exercise Therapy and Cognitive Behavioural Therapy 
Graded Exercise Therapy (GET) and Cognitive Behavioural Therapy (CBT) tailored 
specifically to ME/CFS are treatment approaches based on the behavioural paradigm and 
play a significant influence on current management approaches (Vink & Vink-Niese 2018). 
The safety and efficacy of GET and CBT for ME/CFS have recently been questioned by a 
number of authors (Kindlon 2017; Sunnquist & Jason 2018; Vink & Vink-Niese 2018; 
Wilshire et al. 2018). Two systematic reviews found poor or little evidence for CBT and 
GET, especially when removing those studies utilising the Oxford criteria from analysis (Nijs 
et al. 2011; Smith et al. 2014). A systematic review by Castro-Marrero et al. (2017) found no 
evidence that these therapies increase a meaningful return to work.  
2.7.3 Activity pacing 
A critical review on activity management (Goudsmit et al., 2012), often termed pacing in the 
ME/CFS literature, found that pacing strategies that encourage pwME to stay within their 
available energy boundaries can assist with stabilisation and possibly reduce the severity of 
exertion related symptoms. A case report that appears to confirm the clinical utility of CPET 
testing followed one person who was instructed to only perform prescribed exercises below 
their anaerobic threshold, established with CPET. At one year follow up, cardiovascular and 
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pulmonary parameters had improved and subjective time to recovery from testing had 
improved by 75% (Stevens & Davenport 2010). Larger longitudinal studies following pwME 
who undertake sequential CPET and follow prescribed exercise parameters would be 
informative as the literature is unclear how much limitation pwME need to place on their 
activity to reduce or avoid PEM with changes in immune function found even at sub maximal 
exercise (Nijs et al. 2010). Additionally, only six percent out of a large cohort (n=1534 ) from 
a community based participatory research study (Holtzman et al. 2019) felt pacing 
completely eliminated PEM.  
2.8 Australian context 
Formal estimates of ME/CFS disease burden in Australia are more than ten years old. A 
report in 1999 (Mathers, Vos & Stevenson 1999) by the Australian Institute of Health and 
Welfare (AIHW) used the EQ-5D+ regression model to estimate Disability Adjusted Life 
Years. The EQ-5D+ is a Health Related Quality of Life instrument used extensively in cost 
analysis related to health which uses an anchored scale where 0 is perfect health and 1 is 
death (Rand-Hendriksen, Augestad & Dahl 2012). The AIHW estimated a mild handicap of 
0.137, moderate 0.449 and severe or profound 0.760 for those meeting the Fukuda criteria 
(Mathers, Vos & Stevenson 1999). Moreover, guidelines for medical professionals were last 
updated in 2002 (Royal Australian College of Practitioners 2002). Significantly, changes in 
medical diagnostic and management guidelines have advanced internationally since 
publication of this guideline (IOM, 2015; NHMRC, 2019) and this review identified no 
published nursing or allied health guidelines.  
There have been a small number of Australian based studies examining symptoms and their 
association with function and QoL. Lowry and Pakenham (2008) used the Fukuda criteria in 
a cross-sectional study of Australian participants to assess the effect of fatigue on physical 
and psychological wellbeing and found fatigue, mental fatigue severity, older age, and female 
gender to be strong predictors of physical functional issues. Although 63% of participants 
reported psychological distress, these had weak positive associations with physical fatigue 
and symptom frequency. One limitation of this study was that it did not distinguish fatigue 
from PEM. In a more recent study Johnston, Staines and Marshall-Gradisnik (2016) used 
self-report of a medical diagnosis and symptom inventories to classify respondents according 
to the ICC or Fukuda criteria. The study did not include a clinical interview to confirm 
meeting either criteria. Overall, across diagnostic criteria, the most prevalent symptoms were 
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fatigue, PEM, cognitive difficulties, pain, sleep, light headedness and sensory problems. 
However, the authors highlighted the problem with using symptom inventories without 
threshold scores or standardised methods for assessing reduction in function when classifying 
participants into diagnostic categories. Presence of a symptom alone may not be adequate to 
distinguish between groups with and without ME/CFS, given that many disease processes 
share similar symptoms. In one study, a third of controls could meet ME/CFS diagnostic 
criteria by symptoms alone whereas when frequency and severity thresholds were applied, 
the misclassification of cases dropped to 5% (Jason et al. 2014). Hence the authors (Johnston, 
Staines and Marshall-Gradisnik, 2016) suggest further studies utilising symptom 
measurement scales that use symptom threshold scores that have been rigorously tested.  
2.9 Measurement of symptoms and outcomes 
Different methods for symptom measurement and definition of ME/CFS have influenced 
interpretation of study findings in ME/CFS. For example, a large international study (n = 37 
724) combined a number of studies and data sets and concluded there is an empirical 
‘chronic fatigue’ state with a core mood component (Hickie et al. 2009). However Jason et al. 
(2010a) note that the factor analysis combined ME/CFS Fukuda and those with a general 
fatigue diagnosis rather than separating ME/CFS diagnosis and other fatigue causing 
illnesses, thus making it difficult to assess which participants have a core mood component to 
their illness. Similarly, a large prospective cohort trial (Harvey et al. 2008) established a dose 
response relationship between a prior psychiatric diagnosis and subsequent development of 
ME/CFS, which was defined as ‘fatigue’ or a self-reported diagnosis of ME/CFS. Although it 
is biologically plausible that previous exposures to stress, including psychological stress, may 
lead to ME/CFS (Chu et al. 2019) it remains that otherwise well powered studies have not 
always been specific in their definitions of ME/CFS. 
Potential issues also arise in scales used to measure symptoms; some conflate fatigue that is 
physical or cognitive in origin, and fatigue that is related to psychological symptoms. One 
common scale used in ME/CFS research is the Chalder fatigue Scale (Chalder et al. 1993). 
The scale has strong internal consistency and is able to distinguish between people with 
ME/CFS and healthy controls but is not able to distinguish between people with ME/CFS and 
depression, lupus or multiple sclerosis (Jason et al., 2011). Additionally, as PEM is a distinct 
symptom construct to ME/CFS, generic scales do not capture this symptom, or they may 
conflate fatigue and PEM (Jason & Sunnquist 2018a).  
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2.9.1 The DePaul Symptom Questionnaire 
The DePaul Symptom Questionnaire (DSQ) (Jason et al. 2010b) uses frequency and severity 
threshold symptom scores to classify ME/CFS participants who meet a number of diagnostic 
criteria. The first version of the questionnaire (DSQv1) developed from operationalising the 
CCC as the criteria was initially developed for clinical practice and not as an operationalised 
research definition (Jason et al. 2010b). The DSQv1 has been shown to reliably differentiate 
between ME/CFS, major depression and healthy controls in a research setting (Murdock et al. 
2017). It has also demonstrates good content validity and test-retest reliability (Jason et al. 
2015c). Recent studies that compare objective measures of autonomic (Kemp et al. 2019) and 
cognitive dysfunction (Zinn, Zinn & Jason 2017) have found the DSQ can adequately 
measure these constructs. To date the author is not aware of any published studies using the 
DSQ to measure symptoms in an Australian cohort.  
2.9.2 Medical Outcomes Study 36-item Short-Form Health Survey 
The SF-36 is a generic measure of self-perception of health status (Ware & Sherbourne 1992) 
and has been used consistently in studies in adults with ME/CFS (Buchwald et al. 1996; 
Hardt et al. 2001; Jason et al. 2017; Kingdon et al. 2018). The SF-36 provides measurement 
of multidimensional health concepts and disease impact on physical, psychological and social 
functioning domains (Ware & Sherbourne 1992) and has shown to be reliable and valid in 
assessing these domains (Brazier et al. 1992; McHorney, Ware & Raczek 1993). It includes 
two domains that specifically examine the respondents overall perception of their health, 
these being the General Health and Vitality (McHorney, Ware & Raczek 1993). In regards to 
ME/CFS, Jason et al. (2011) found the Role Physical, Social Functioning and 
Vitality subscales had the best sensitivity and specificity to distinguish between those with 
ME/CFS and those without whereas the Role Emotional performed the worst. Because the 
DSQv1 uses these sub scales to establish ‘substantial reductions in function’ (Jason & 
Sunnquist 2018b) and due to the widespread use of the SF-36 in the ME/CFS literature it was 
chosen as part of the full study this thesis draws from (See Appendix 2 for literature search of 
the SF-36). Some concerns have been documented in regards to the utility of this 
questionnaire in the ME/CFS population. For example, Davenport et al. (2011) found the 
physical function, body pain, general health, vitality and social domains were able to predict 
recovery within one day of CPET in a combined sample of sedentary controls and ME/CFS. 
However, when they considered group differences over one week there was no statistical 
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difference. The authors suggest this may be partially explained by a number of subscale 
scores being rated 0 by the ME/CFS participants at both time points. Furthermore, Murdock 
and colleagues (2017) also found possible floor effects in the Role Limitations sub-scale with 
89% of patients scoring zero. The floor effects do raise concerns regarding the scales utility 
in any study looking to measure variance in function, change over time, or adverse effects 
from an intervention such as a further reduction in function. For this reason, floor and ceiling 
effects will be reported on in the present study if they occur.  
2.10 Conclusion  
This chapter identified several intersecting themes within the literature regarding accurate 
measurement of the ME/CFS population in regard to diagnosis, functional impairment and 
measurement and interpretation of symptoms. There is considerable heterogeneity of study 
participants due to varying methods for selecting participants for research, in regard to 
diagnostic criteria, study design and feasibility of accessing more severe participants. The 
different interpretation of symptoms, exemplified in the diagnostic criteria, emerged as a 
point of difference that has influenced treatment approaches. The symptom PEM emerged as 
disease specific; as PEM is unique it cannot be captured using generic fatigue scales. There 
are also outstanding questions regarding the inclusion of orthostatic intolerance in the IOM 
clinical criteria and the omission of pain. This leads to the aim of the present study which is 
to explore the relationship between symptoms and their association with everyday functional 
capacity and QoL using the ME/CFS specific symptom measurement tool the DSQv1, in 
order to extend the research base in Australia. This may identify further areas for research in 
relation to appropriate health care of individuals with ME/CFS.  
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Chapter 3 Method 
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3.1 Overview and study design 
This chapter details the methods used in the current study and will describe the research 
design, data collection and management, data analysis approach and ethical considerations. 
Building on Chapter 2, further details are provided regarding the DSQv1 and SF-36. A cross-
sectional survey design was employed for this study. Descriptive and correlation statistics 
were used to explore the symptoms, function, and QoL, and the relationships between them, 
in a cohort of Australians who met the IOM clinical diagnostic criteria. Descriptive research 
is a non-experimental research method used to describe and summarise data that is collected 
in a systematic fashion, but it does not seek to manipulate variables (Da Costa & Schneider 
2016). Correlation statistics measure the extent to which two variables are related hence there 
is not a dependent and independent variable as causality is not being established (Pallant 
2016). In the present study operationalised definitions, in the form of questionnaires, allowed 
for subjective experiences such as symptoms and self-perception of functional capacity and 
QoL to be consistently categorised and the questionnaires were completed without the 
researcher present. Self-report measurement of symptoms is as an important element in 
understanding illness experience from the patients’ point of view (Haywood, Staniszewska & 
Chapman 2012; Valderas & Alonso 2008) that may strengthen problem identification in 
physical or psychosocial domains with the long term aim of improving service design (Hahn 
et al. 2007).  
3.2 Measures:  
Participants completed the following self-reported questionnaires on demographics, 
symptoms, function and QoL (listed below). 
3.2.1 Sociodemographic data 
Participant reported their: age, gender, marital status, highest level of education, language 
spoken at home, employment status, length of time that they had been experiencing 
symptoms and length of time that they had had a diagnosis.  
3.2.2 ME/CFS symptoms  
The DSQv1 psychometric properties have been discussed in chapter one section 2.8.1 hence 
this section aims to provide an explanation of how the scale works and how the symptom 
domains were created for the present study. The DSQv1 has a core symptom inventory of 54 
items which are organised under domain headings, these being: fatigue, PEM, sleep, pain, 
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neurocognitive, autonomic, neuroendocrine and immune. Participants rate each symptom 
separately for frequency and severity on 5-point Likert-type scales: 0=‘none of the time’, 1=a 
little of the time, 2=about half the time, 3=most of the time, and 4=all of the time over a 
retrospective six month period at time of completing the questionnaire. For this study the 54 
symptoms and their original grouping (Jason et al. 2010b) were used to devise composite 
symptom domains as in a study by Jason et al. (2017) and these were: Fatigue (one item); 
PEM (six items e.g., “dead heavy feeling after exercise); sleep (five items e.g., “problems 
with “unrefreshing sleep”); pain (seven items e.g., “muscle pain”); neurocognitive (thirteen 
items e.g., “Absent mindedness”); autonomic (seven items e.g., “bladder problems”); 
neuroendocrine (ten items e.g., “feeling hot/cold for no reason”); immune (five items e.g., 
“sore throat”). Scoring of the scale involved two steps: 1) individual frequency and severity 
scores for each symptom were multiplied by 25 and averaged together to create a composite 
score on a 100-point scale with higher scores indicating higher symptom severity (Jason and 
Sunnquist, 2018b) and 2) the domains were created by adding together then averaging the 
composite severity scores of items within each domain. Each domain had a possible 
composite score ranging from 0 to 100 with higher scores indicating higher domain severity. 
The DSQv1 is available on REDCap's shared library (Harris et al., 2009).  
3.2.3 Everyday function and QoL 
The psychometric properties of the SF-36 are discussed section 2.9.1 hence this section will 
further elaborate on the structure of the scale. The SF-36 comprises eight subscales: Physical 
Functioning (such as ability to climb stairs, running, lifting or walking); Role Physical (role 
limitations such as employment due to physical health problems); Bodily Pain (intensity and 
interference with normal activities); General Health perceptions (respondents perception of 
their health status); Social Functioning (impact of physical or emotional problems on social 
interactions and capacity); Vitality (measure of perception of energy and fatigue); Role 
Emotional (role limitations due to emotional problems) and Mental Health (anxiety, 
depression and psychological well-being). Respondents are asked to respond to each question 
in regard to the last month at the time of completing the questionnaire. These sub scales can 
be converted to two summary measures: physical component summary (PCS) and mental 
component summary (MCS). Responses to questions defining each SF-36 domain were 
combined and transformed to 100 point scales with 100 indicating better health status (Ware 
et al., 1994). The MCS, in addition to two specific mental health domains, includes Social 
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Function Vitality. The way the questions are framed for these two domains could reflect 
limitations due to mental or physical related issues (McHorney, Ware & Raczek 1993) hence 
the full eight subscales will be used to allow for a better exploration of mental and physical 
health. 
3.2.4 Case definition 
In addition to a self-reported diagnosis of ME/CFS by a medical practitioner, inclusion for 
the present study specified meeting the IOM clinical diagnostic criteria. This was established 
by applying algorithms supplied by the DSQv1 authors that uses symptom threshold scores 
(Jason and Sunnquist, 2018b).  
3.3 Setting, recruitment and participants 
3.3.1 Setting and recruitment 
Using a cross-sectional design, participants were recruited online through advertisements on 
social media, support organisation websites and newsletters (Appendix 3) from November 
2017 until May 2019. The author started participating in recruitment from November 2018 
after an amendment to the ethics application. Recruitment followed an established pathway 
(Figure 2). Potential participants undertook the screening questionnaire (Appendix 4) via the 
online platform which was SurveyMonkey and these were assessed by the researchers. 
Clarification and assessment of complex cases, especially where the history of head trauma 
was unclear, were referred to the lead investigator. If potential participants were identified as 
eligible they were sent, via their nominated email address, a link which contained the 
participation information sheet (Appendix 5), online consent form (Appendix 6) study 
questionnaires and a unique identification number (see following appendices for the data 
pertaining to this thesis: Appendix 7 demographics; Appendix 8 DSQv1 and Appendix 9 SF-
36). Those who were not eligible were sent an email with an explanation of why they did not 
meet study criteria and thanking them for their time. One reminder was sent to each eligible 
participant if they had not started or not completed the consent form and questionnaires and a 
thankyou email was sent to all participants who completed the full questionnaire (Appendix 
10 for all email templates). 
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Figure 2. Study recruitment procedure 
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3.3.2 Inclusion and exclusion criteria  
The study comprised adults (aged 18-65 years) who self-reported a diagnosis of ME/CFS by 
a suitably qualified Medical Practitioner. Exclusion criteria were a diagnosis of psychotic, 
bipolar or related disorder; a history of brain injury or other neurological illness; a history of 
alcohol or illicit drug abuse; pregnancy; an inability to speak or read English; and 
uncorrected visual difficulties such that a participant is unable to read and respond to 
questions. They were also excluded for the present study if they did not meet IOM clinical 
criteria. This was an additional step once participants had completed the full study.  
3.3.3 Sample  
As identified in the literature review, comparison of ME/CFS participants is difficult when 
each study utilises their own interpretation of the chosen criteria. The DSQv1 provides a 
standardised method of case ascertainment in these circumstances. In the present study, 
diagnosis according to the IOM clinical criteria was ascertained from participants responses 
to the DSQv1 and SF-36 via algorithms developed by Jason and Sunnquist (2018b). 
3.4 Procedure for data entry and management 
3.4.1 Data collection 
As previously mentioned, the data collection tool was SurveyMonkey which was password 
protected. SurveyMonkey was used for both the initial screening questionnaire and for the 
full study. Data was extracted from SurveyMonkey to an excel spreadsheet in order to assess 
answers to the screening questionnaire. A separate participant tracker was established for 
those participants who met eligibility criteria in order to send reminders and a thankyou email 
if the survey was completed. The tracker was visible to the author and the lead investigator 
and was password protected.  
3.4.2 Data entry 
Data from SurveyMonkey was extracted to Excel and then to SPSS by a psychology honours 
student who also classified participants into the IOM criteria (Jason and Sunnquist, 2018b) 
and scored the SF-36 domains (Ware et al., 1994). Demographics, the DSQv1 symptom raw 
scores (frequency and severity on scales of 0-4), the combined DSQv1 domain scores 
(specified by the author) and SF-36 domain scores were supplied to the author. The original 
data is stored by the lead investigator. 
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3.5 Data analysis 
Prior to summarising data and performing analysis, data was examined to assess assumptions 
for reporting of continuous variables and for correlation analysis. Descriptive statistics were 
obtained to describe the sample, summarise data and explore range of scores (mean, median, 
ranges and percentages); missing variables; and outliers. Normality of distribution was 
assessed with frequency histograms and Kolmogorov-Smirnov to guide descriptive and 
bivariate analysis. Correlation coefficients were interpreted as follows: .50 is strong; .40 is 
moderate to strong; .30 is moderate; .20 is small to moderate; .10 is weak (Cohen 1988). The 
criterion for statistical significance was set at p < 0.05. All data were analysed using IBM 
SPSS Statistics Software (version 25). 
3.5.1 Ethical approval, informed consent and considerations  
Ethical approval was received from the University of Tasmania Health & Medical Human 
Research Ethics Committee H0015630 and the study complied with the World Medical 
Association Declaration of Helsinki and the National Statement on Ethical Conduct in 
Human Research 2007. Data was deidentified for analysis. Participants could withdraw from 
participation or have their data removed at any point. As people with pwME are known to 
fatigue from cognitive tasks, participants were encouraged to have a family member or friend 
present when reading and signing the consent form however this was not a requirement of 
informed consent. Additionally, to allow for pacing of activity and reduction of fatigue, the 
questionnaire platform enabled the survey to be saved and completed over a number of 
sessions if required. Participants were able to opt to complete a hard-copy version of the 
consent form and study questionnaires, which was mailed to them with a stamped, return 
address envelope. There was no financial reimbursement. 
3.6 Summary 
This chapter detailed the methods used in the current study. This was a cross-sectional study 
which utilised two reliable and validated instruments for collecting self-reported symptom 
severity, everyday functional status and QoL. Data collection and management, participant 
eligibility and ethical considerations were discussed. The following chapter will detail the 
key findings of the study.  
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Chapter 4 Results 
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4.1 Overview 
This chapter presents study results, including selection of the final sample and how the data 
was explored to guide descriptive and correlation analysis. A summary of some of the key 
findings is provided with each step of the analysis and a brief summary to conclude the 
chapter is provided.  
4.2 Sample 
4.2.1 Meeting case definition and final cohort for analysis 
Out of 240 eligible participants who were sent links to the full study, two contacted the 
author by email to say they were not well enough to complete the study and they were 
thanked for their time and interest in the study. By May 2019 there were 191 who had 
completed the consent form and the required questionnaires for this study. Of these 34 did 
not meet IOM criteria hence they were excluded from further analysis. One participant was 
out of the age range hence they were also excluded from analysis. This participant may have 
incorrectly entered their age in the final study as they would have been excluded through 
initial screening if they had entered their age as over 65. This left 156 participants for the 
present study. 
4.2.2 Missing data, out of range scores and outliers  
There was missing data for relationship status (n=149). There was one missing value for 
“years since symptoms began” and two missing values for “yeas since diagnosis”. These 
variables were not required for the main correlation analysis and so no methods for 
replacement of missing data were undertaken. There were no missing scores for the DSQv1 
or SF-36 and scores for these domains were within range. SF-36 and DSQv1 domain scores 
were converted to z scores in SPSS to assess outliers and all scores were within the specified 
range of -3.29 and 3  indicating no outliers (Tabachnick & Fidell 2016). 
4.2.3 Analysis assumptions 
Cronbach’s alphas were calculated for the DSQv1 domains, except for fatigue as it is a stand-
alone symptom in the inventory. These indicated excellent internal consistency with values 
between 0.80 – 0.92. Histograms for continuous data were visually inspected and these were 
not normally distributed. Kolmogorov-Smirnov for the SF-36 domains were all significant 
indicating violation of assumption of normality (Pallant, 2016) and this was the case for the 
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DSQv1 domains of PEM, pain, autonomic and immune hence scores are reported as median 
and Interquartile Range (IQR). To assess if there were symptoms associated with worse 
functional outcomes the non-parametric Spearman’s correlation coefficients (rs) were 
calculated between the DSQv1 domains and the SF-36 domains including the component 
summaries.  
4.2.4 Sociodemographic Participant characteristics 
The participant characteristics, including sociodemographic characteristics and ME/CFS 
related factors such as employment status are described in Table 2. The majority of 
respondents were female (88.5%) and highly educated. In all, 51 (32.7%) were in paid 
employment and 105 (67.3%) were not in paid employment. The median time that 
respondents had been experiencing symptoms was 11.21 years (IQR 4.79 – 22.83) and the 
median time that they had received a diagnosis was 5.64 years (IQR 2.54 - 12.5). 
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Table 2. Demographics 
 
Characteristics   n  %  
Sex       
Male  18 11.5  
Female  138 88.5  
Age, in years* 39.7 (12.3)        - 
Educational level   
 
  
Highschool only 23 14.7 
Technical/Diploma 45 28.8 
First degree or higher  88 56.4 
Language other than English     
Yes 15 9.6 
No 141 90.4 
Relationship status     
Never married 60 49.3 
Married/defacto 73 49.3 
Separated/divorced 15 10.1 
Work reduced due to symptoms       
No/unsure 14 9.0 
Yes 53 34.0 
No longer work 89 57.1 
Currently in Paid employment   
No 105 67.3 
Yes 51 32.7 
Years experienced symptoms+ 11.2 1(4.879–22.83) 
Years with a diagnosis+ 5.64 (2.54 - 12.5)   
 
         *mean (Standard deviation) +median (interquartile range), counts and  
         percentages may not reach 100% if there was were missing values 
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4.2.5 DSQv1 Symptoms 
The full DSQv1 inventory is presented in Table 3 and indicates which symptoms make up the 
individual domains. Out of the eight DSQv1 symptom domains, the highest scores were for 
fatigue (75.00 IQR 75.00 – 87.50) followed by PEM (72.00 IQR 60.00 – 82.50) and then the 
neurocognitive domain (54.81 IQR 43.27 – 64.42). 
Table 3. DSQv1 symptoms 
Symptoms n=156*+ 
Fatigue  75.00 75.00-87.50 
Post-exertional Malaise   
Dead heavy feeling after starting exercise 75.00 62.50-87.50 
Next Day soreness 75.00 62.50-87.50 
Mentally tired after slightest effort 62.50 50.00--87.50 
Minimal exercise makes physically tired 75.00 62.50-87.50 
Physically drained or sick 75.00 50.00-87.50 
Sleep   
Feeling unrefreshed after you wake up 87.50 75.00-100.00 
Need to nap daily 62.50 28.13-75.00 
Problems falling asleep 50.00 37.50-75.00 
Problems staying asleep 50.00 28.13-75.00 
Waking up early 37.50 25.00-62.50 
Sleep all day and stay awake all night 00.00 00.00-37.50 
Pain   
Pain or aching in your muscles 68.75 50.00-87.50 
Pain/stiffness/tenderness more one joint 62.50 40.63-87.50 
Eye pain 25.00 00.00-50.00 
Chest pain 25.00 00.00-37.50 
bloating 43.75 25.00-62.50 
Abdominal/stomach pain 37.50 25.00-50.00 
Headaches 50.00 37.50-62.50 
Neurocognitive   
Muscle twitches 62.50 37.50-75.00 
Muscle weakness 50.00 25.00-75.00 
Sensitivity to noise 50.00 37.50-75.00 
Sensitivity to bright lights 50.00 25.00-75.00 
Problems remembering things 62.50 50.00-75.00 
Difficulty paying attention for a long time 75.00 62.50-87.50 
Difficulty finding the right word to say 62.50 50.00-75.00 
Difficulty understanding things 37.50 25.00-75.00 
Only able to focus on one thing at a time 62.50 50.00-62.50 
Unable to focus vision and/or attention 50.00 25.00-62.50 
Loss of depth perception 25.00        00.00-37.50 
Slowness of thought 50.00 37.50-75.00 
Absent mindedness or forgetfulness 62.50 37.50-75.00 
Autonomic   
Bladder problems 25.00 00.00-50.00 
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Irritable bowel problems 50.00 25.00-50.00 
Nausea 25.00 25.00-75.00 
Unsteady on feet like you might fall 37.50 25.00-50.00 
 Trouble catching your breath 37.50 25.00-50.00 
 Dizziness or fainting 37.50 25.00-37.50 
 Irregular heart beats 25.00 00.00-37.50 
 Neuroendocrine   
 Losing or gaining weight without trying 50.00 06.25-75.00 
No appetite 25.00 00.00-50.00 
Sweating hands 00.00 00.00-25.00 
Night sweats 25.00 12.50-50.00 
 Cold limbs arms legs hands 37.50 25.00-62.50 
 Feeling chills or shivers 25.00 00.00-50.00 
Feeling hot or cold for no reason 50.00 25.00-62.50 
Feeling like you have a high temperature 25.00 25.00-50.00 
 Feeling like you have a low temperature 25.00 00.00-37.50 
Alcohol intolerance 50.00 00.00-87.50 
Immune   
Sore throat 37.50 25.00-62.50 
Tender/sore lymph nodes 37.50 25.00-62.50 
Fever 18.75 00.00-25.00 
Flu like illness 50.00 25.00-62.50 
Smells/foods/chemicals feel sick 50.00 37.50-62.50 
   aHigher scores indicate higher severity of symptoms  
   +median (interquartile range) 
 
Table 4 provides the domain scores for the DSQv1. Out of the eight DSQv1 symptom 
domains, the highest scores were for fatigue (75.00 IQR 75.00 – 87.50) followed by PEM 
(72.00 IQR 60.00 – 82.50) and then the neurocognitive domain (54.81 IQR 43.27 – 64.42).  
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Table 4. DSQv1 symptom domains 
DSQ Domains n=156*+ 
Fatigue  75.00 75.00 – 87.50 
PEM 72.50 60.00 – 82.50 
Sleep 50.00 37.70 – 62.50  
Pain 47.92 31.25 – 58.33  
Neurocognitive 54.81 43.27 – 64.42 
Autonomic 33.93 23.21 – 44.64 
Neuroendocrine 32.50 25.00 – 41.25  
Immune 40.00 25.00 – 50.00 
       *Higher scores indicate higher severity of symptoms  
       +median (interquartile range) 
 
4.2.6 Everyday function and QoL  
SF-36 scores are presented in Table 5. Out of the eight SF-36 subscales, the best preserved 
function was within the Role Emotional and Mental Health subscales. However, these 
subscales exhibited a large range of scores, especially in the Role Emotional sub scale (IQR 
33 – 100) with 53.2% scoring 100 (the highest possible score). The worst score was in the 
Role Physical subscale, which asks questions regarding problems with work or other 
activities due to physical health problems, where 83.3% scored 0 (the lowest possible score). 
Three other domains also had a large proportion of 0 scores: Vitality (26.9%), Social 
Functioning (25.0%) and Role Emotional (22.4%,).  
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Table 5. SF-36 domain scores 
SF-36 n=156b+ 
Physical Function 30.00 20.00 – 40.00 
Role Physical 00.00 00.00 - 00.00 
 Body Pain 32.00 22.00 – 52.00 
General Health 20.00 10.00 – 30.00 
Vitality 10.00 00.00 – 20.00 
Social Functioning 25.00 03.25 – 50.00 
Role Emotional 100.00 33.00 – 100.00 
Mental Health 64.00 48.00 – 76.00 
PCS 21.00 15.25 – 28.00 
MHCS 39.00 27.25 – 48.00 
             bHigher scores indicate better function 
         +median (interquartile range) 
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4.2.7 Relationship between symptoms, everyday function and QoL 
Spearman’s correlations between DSQv1 symptom domains and SF-36 scores are presented 
in Table 6 with the domains that constitute the two summary scores grouped together.  
 
Table 6. Spearman’s Correlation matrix between SF-36 and DSQv1 domains           
Physical Health Mental Health 
Component 
summaries 
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Fatigue -.441** -.138 -.376** -.353** -.444** -.414** -.139 -.104 -.539** -.380** 
PEM -.469** -.168* -.447** -.292** -.467** -.526** -.121 -.095 -.596** -.401** 
Sleep -.238** -.003 -.345** -.183* -.128 -.185* -.172* -.112 -.322** -.227** 
Pain -.289** -.137 -.606** -.233** -.155 -.141 -.074 -.027 -.506** -.148 
Neurocog -.243** -.237** -.353** -.182* -.259** -.207** -.155 -.089 -.414** -.238** 
Autonomic -.190
* -.187* -.424** -.182* -.128 -.198* -.134 -.013 -.375** -.196** 
Neuroenodo -.155 -.127 -.316** -.177* -.113 -.243** -.164* -.123 -.309** -.241** 
Immune -.208** -.082 -.321** -.237** -.169* -.128 -.076 -.008 -.347** -.138 
*Correlation is significant at the 0.05 level (2-tailed) 
** Correlation is significant at the 0.01 level (2-tailed) 
 
4.3 Summary 
The current chapter presents the study results with a summary of some of the key findings at 
each step of the analysis. A correlation matrix is provided to answer the research question of  
“Which symptoms are associated with everyday functional impairment and reduced QoL in 
ME/CFS?”. The findings from these results are discussed in the following chapter, with 
recommendations for practice and further research and a conclusion to the thesis.  
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Chapter 5 Discussion 
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5.1 Introduction 
It is evident from the literature review and from the present study that pwME experience a 
number of symptoms, which may impact on their capacity to participate in a range of 
everyday activities and their QoL. Fatigue and PEM are often associated with reduced 
everyday function such as reduced employment and capacity to undertake ADL’s. 
Additionally, autonomic related symptoms, such as orthostatic intolerance and pain also 
emerged in the literature review as areas that are currently under investigation for their 
prevalence, impact and relevance to clinical practice. This chapter will discuss the study 
findings, with reference to the study objectives and in the context of the broader literature on 
ME/CFS. Recommendations for further research and practice are provided with a focus on 
the implications symptoms and everyday functional limitations may have in the health care 
context based on the study findings. The health economic implications are also discussed. 
Strengths and limitations of the study are discussed and a conclusion to the thesis is also 
provided.  
5.2 Key findings 
The aim of this thesis was to explore the symptoms associated with everyday functional 
impairments and QoL in ME/CFS. The objectives being to 1) describe participants 
demographic characteristics and 2) explore symptoms (using the DSQv1) and their 
association with function and QoL (using the SF-36) with ME/CFS reported by a cohort of 
Australians to answer the research question: 
 “Which symptoms are associated with everyday functional impairment and reduced QoL in 
ME/CFS?”. As such, the key findings were:  
I. All symptom domains had a strong association with everyday functional impairment 
and reduced QoL due to physical problems. PEM, fatigue and pain had the strongest 
association overall. 
II. The association between symptoms and mental health problems were weak.  
III. More than half of the respondents indicated that they were no longer able to work. 
IV. There was a large gap in time between when respondents first noticed symptoms and 
when they received a diagnosis. 
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5.3 Demographics 
There was a large proportion of female respondents compared to males in the present study 
which is a common finding in the ME/CFS literature (IOM, 2015). As identified in the 
literature review, further population based studies are required to assess the true ratio of 
males to females with ME/CFS due to some recent discrepant findings using large scale data 
mining (Valdez et al. 2019). This has important implications for biological research as there 
is an increasing awareness of the influence of biological differences between males and 
females in disease processes (Regitz-Zagrosek 2012). 
In the present study, a large proportion of participants had undertaken higher levels of 
education hence this cohort represents a reasonably well educated group of pwME. These 
levels of education are similar to a recent cross-sectional study in Australia with similar 
recruitment methods (Johnston et al., 2016) and a prospective/retrospective cohort study from 
clinical referrals in the United States (Unger et al., 2017). In comparison, samples drawn 
from a United Kingdom Biobank study (Kingdon et al., 2018) had a more even spread of 
educational attainment spanning from high school only through to higher education and post-
graduate study. There may be a range of factors influencing the discrepancy in education 
levels across studies including country specific access to health care and wider recruitment 
methods for the biobank sample (Kingdon et al., 2018). It is unclear what the implications are 
for the high levels of education in the present study. Higher levels of education are associated 
with a range of health benefits in the general population including ability to access medical 
care and health literacy (Australian Institute of Health and Welfare (AIHW), 2018; Hahn & 
Truman, 2015). Despite the high levels of education and capacity to obtain a diagnosis, there 
was a reasonably large interval between time participants had been experiencing symptoms 
and time that they were diagnosed. The implications of a delayed diagnosis are unclear. One 
study suggested that a delay may increase risk of having a more severe course of illness 
(Pheby & Saffron 2009) however this has not been replicated in further studies. Certainly 
early changes in activity in response to energy restrictions would make sense given what is 
known about the effects ME/CFS has on aerobic metabolism (Stevens et al., 2018). Access to 
health care practitioners who can guide this would appear to be one benefit of an early 
diagnosis. An additional consequence may be that with a delay in diagnosis pwME may be 
presenting with secondary complications, making assessment and management more 
complex (Strassheim et al. 2017).  
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A reoccurring theme in the literature is that pwME often seek an explanation for their 
symptoms for many years before receiving a medical diagnosis of ME/CFS (IOM 2015). 
There is a paucity of data on population prevalence and diagnostic rates in Australia although 
a recent report from the Australian patient support group Emerge found 40% reported 
receiving a diagnosis within one to two years and fifteen percent took ten or more years 
(Emerge Australia, 2018). The literature review for this thesis identified that some of the 
barriers to making a diagnosis for health care workers were knowledge, confidence and 
attitudes regarding ME/CFS. A further structural barrier was identified in a community based 
epidemiological study in the United States (Jason et al. 1999) which found medically 
underserved minority groups, particularly Latino groups, had higher rates of ME/CFS but 
lower rates of a medical diagnosis. Although the Australian health care system is different to 
the United States, there still remain issues of equity of access to health care services. In 
particular, rurality, lower sociodemographic status and being Aboriginal or Torres Strait 
Islander are all associated with poorer health outcomes (Thomas, Wakerman & Humphreys 
2015). It is not known what the Australian specific factors are that may lead to a delay in 
diagnosis of ME/CFS and this warrants further investigation. 
In regards to employment, in the present study over half the participants were not in paid 
employment. These findings are consistent with previous research in Australia where 
Johnston et al. (2016) found just over half of the participants reported being unemployed. 
Similar rates of unemployment were found in a large cross-sectional study in Spain (Castro-
Marrero et al., 2019). In the aforementioned cohort study in the United States with physician 
diagnosed ME/CFS (which does not specify criteria) a higher percentage, nearly three 
quarters, were unemployed (Unger et al., 2017) which may reflect severity of illness as 
participants were accessing specialist services. All three studies used different methods for 
diagnosis however rates of unemployment were consistently high. One implication of this 
this is that whilst there is outstanding questions regarding the specificity of diagnostic 
criteria, pwME experience high rates of unemployment across diagnostic criteria. Further 
examination of the present data could look for factors associated with work retention such as 
symptom severity, delay in diagnosis or length of illness. Future studies could examine the 
positive factors that enable retention of employment such as external support structures (the 
role of a carer, supportive work environment, active management of particular symptoms) of 
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which there is little existing published data beyond reports of clinician related experience 
(Carruthers et al. 2012).  
5.4 Symptoms and their association with everyday function and QoL 
In the present study a composite symptom severity score was used from a combined 
frequency and severity rating to estimate the overall perceived “impact” of a symptom. In the 
full 54 item symptom inventory, the highest scoring symptom was ‘feeling unrefreshed when 
you wake up”, followed by “fatigue” and then “dead heavy feeling after starting exercise”. 
Often studies report prevalence of symptoms, for example when using the DSQv1 Jason et al. 
(2014) found that the most prevalent symptoms were fatigue, PEM, neurocognitive problems, 
and unrefreshing sleep. Similarly, fatigue, PEM and unrefreshing sleep were the most 
prevalent symptom in the study by Unger et al. (2017) that used the Centres for Disease 
control symptom inventory (Wagner et al. 2005). In an Australian study, the most prevalent 
symptoms were fatigue, PEM, cognitive difficulties, pain, sleep, light headedness and 
sensory problems (Johnston, Staines & Marshall-Gradisnik 2016). Although there is a 
difference in how symptoms are measured a similar symptom pattern is apparent in the 
present study with symptoms related to sleep, fatigue, PEM and neurocognitive problems 
being of high severity. This is also reflected in the domain scores with the highest domain 
score being fatigue, followed by PEM and then the neurocognitive domain. Although the 
present study did not include a measure of disease severity, the extreme limitations 
experienced by some participants can be seen in the Physical Function subscale which 
provides details concerning specific physical limitations. The lowest rating “limited a lot” 
were given for climbing one flight of stairs (21.1%); 28.8% walking one block (28.8%) and 
bathing or dressing yourself (9%). 
5.4.1 PEM and fatigue 
The PCS had moderate to strong negative correlations with all the DSQv1 domains. This was 
also the case for the MCS apart from pain and immune which were weak correlation 
coefficients and did not reach statistical significance. Overall the PCS had the strongest 
negative correlations with PEM, fatigue and pain. This is consistent with existing literature 
that identifies PEM as associated with functional impairment due to problems with energy 
production (McGregor et al., 2019, Stevens et al., 2018). Clarifying the symptom of PEM as 
opposed to other types of fatigue, including both physical and cognitive fatigue, in order to 
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both distinguish ME/CFS from other disease processes that include severe fatigue and to 
understand the complexity of fatigue within ME/CFS itself, is an ongoing pursuit in the 
biological and symptom measurement literature (McGregor et al. 2019). Recent 
developments to the DSQ PEM domain found asking participants PEM duration further 
distinguished those with ME/CFS from multiple sclerosis or post- polio Syndrome which are 
both associated with high levels of fatigue (Joseph et al., 2018). There is very limited 
literature on successful management approaches for fatigue or PEM apart from pacing (IOM, 
2015). This highlights the need for clinician awareness of the complex nature of fatigue, and 
the importance of asking clarifying questions to discover if there are symptoms 
distinguishing fatigue and PEM so that appropriate activity management strategies can be 
implemented.  
5.4.2 Pain 
Although pain is not specified as an essential symptom for diagnosis according to the IOM 
criteria, it is identified as an important symptom to assess and manage (IOM, 2015). In the 
present study the severity of “pain or aching in your muscles” was reasonably high in the full 
DSQv1 symptom inventory. This is similar to a community participatory study exploring the 
DSQ symptoms which found participants identified muscle pain as one of the most common 
symptoms associated with PEM (Holtzman et al., 2019).  
The DSQv1 pain domain and the SF-36 pain domain had the strongest negative correlation 
overall which may indicate that these two domains are measuring similar underlying 
constructs. It certainly indicates that for this group pain is often severe and is associated with 
reductions in everyday function. Pain also had moderate, statistically significant negative 
correlations with Physical Function and General Health. The correlations between pain and 
Role Emotional and Mental Health were very weak. This is surprising as pain is often 
associated with depression in ME/CFS (Strand et al. 2019).  
5.4.3 Orthostatic intolerance and neurocognitive symptoms 
Orthostatic intolerance, which is attributed to changes in autonomic function, is one optional 
symptom in the IOM criteria. The negative correlation between the autonomic symptom 
domain and SF-36 Pain and PCS were strong to moderate and although it reached statistical 
significance for the MCS it was a weak coefficient. The individual items that traditionally 
indicate orthostatic intolerance had reasonably low severity scores, these being: “unsteady on 
your feet like you might fall”; “trouble catching your breath”; “dizziness of fainting” and 
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“irregular heartbeats”. However, the reasonably strong negative correlation with the PCS and 
Pain suggests the inclusion of orthostatic intolerance in the IOM criteria makes sense from at 
least a clinical perspective. Indeed, orthostatic intolerance is one symptom that is relatively 
amenable to both non-pharmacological and pharmacological interventions (Reynolds et al. 
2014). Furthermore, there is evidence to suggest that the traditional measurements of 
orthostatic intolerance may not always reflect the pervasiveness of orthostatic related cardiac 
output in ME/CFS. A large study (n=150) found, even without traditional indicators of 
orthostatic intolerance on tilt table test such as a decrease in blood pressure or sustained rise 
in heart rate, participants had lower stroke volume and cardiac output (van Campen and 
Visser, 2018). These changes were not statistically different when stratified for participant 
severity, suggesting the changes were not due to deconditioning. There is also evidence that 
autonomic related cerebral blood flow changes may have a more pervasive effect on 
symptoms such as PEM, pain and neurocognitive function (Nijs & Ickmans 2013), hence, 
these symptoms may be interrelated and treating one may have an influence on the other.  
5.4.4 Mental Health and subjective wellbeing 
The MCS of the SF-36 includes Vitality and Social Functioning domains which could be due 
to either physical or mental health issues due to the way the questions are framed 
(McHorney, Ware & Raczek 1993). The Role Emotional and Mental Health sub domain 
scores were the highest scoring domains overall (indicating better function) and these had 
weak negative correlations with all DSQv1 symptom domains. However, Vitality was the 
second lowest scoring domain after Role Physical thus the association between symptoms 
and mental health function are unclear in the present study. It could be concluded that given 
the high scores in the two specific mental health domains that reductions in Social and 
Vitality were scored according to physical and not mental health reasons by participants. The 
Role Emotional sub scale did have a large number of participants scoring at the ceiling of the 
scale (53.2% scoring 100). This is a three item domain that asks for binary responses in 
regards to effect of emotional problems on regular activities: 1) cutting down activities 2) 
accomplishing less than participant would like and 3) being less careful in work or activities 
than usual (Ware, Keller & Kosinski 1994). Given the large proportion of respondents not 
working due to symptoms, rating high on this scale may simply be due to the scale not 
measuring relevant factors to this group of participants. The relatively high mental health 
scores may also reflect a response shift in this population whereby participants have adapted 
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to their illness and accepted their limitations (Reynolds, Brown & Jason 2009). Stratification 
by length of illness may be a further area of investigation.  
There are some contradictory findings on the prevalence and role mental health issues play in 
ME/CFS. Mental health problems are not uncommon in chronic health conditions and may be 
both a consequence of illness burden, such as change in capacity, physiological changes in 
neurobiology (Katon 2011) or simply a co-diagnosis. Social isolation in particular is known 
to be associated with poor physical and mental health outcomes in chronic illness (Ubido & 
Scott-Samuel 2014). ME/CFS is known to lead to social isolation via restrictions in 
education, employment and capacity to participate in recreational activities (Anderson, Jason 
& Hlavaty 2014). A strong negative association between physical symptoms and social 
isolation is supported in the present study with PEM and fatigue having strong to moderate 
negative correlations with the Social domain. In a large (n=960) multi-site clinical 
epidemiology study (Bateman et al., 2015), that included physician diagnosis and assessment 
of ME/CFS, 60% of participants reported a co-morbid mental health issue and this 
contributed to illness severity over time. However, when assessing co-morbid multipliers of 
symptom frequency, severity and function in ME/CFS Natelson et al. (2019) found no 
significant difference between those with and without a co diagnosis of anxiety or depression. 
Many studies find a consistent preservation of SF-36 mental health scores in comparison to 
the low scores in the Physical, Role Physical and Vitality sub scales of the SF-36 (Jason et al. 
2016; Kingdon et al. 2018; Unger et al. 2016) hence the present study is similar in this 
respect to other studies utilising the SF-36.    
5.4.5 Restricted range of scores 
It was surprising that there were mostly weak correlations between the DSQv1 symptom 
domains and the SF-36 Role Physical given the extreme limitations indicated by some 
participants in the Physical Function subscale. The DSQv1 neurocognitive domain had a 
small to moderate negative correlation but all other correlations were weak. Additionally, the 
large percentage of participants not in paid work would suggest significant role limitations 
hence one would expect a range of symptoms to have strong negative associations with this 
SF-36 sub scale. This domain had a high proportion of respondents at the floor of the scale. 
Hence the low correlations may be due to “restricted range” that will reduce correlation 
coefficients (Pallant 2016). As a cross sectional study these effects are not particularly 
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concerning, however they may indicate a limitation in the questionnaire to measure change 
over time in response to an intervention. 
5.5 Strengths and limitations 
5.5.1 Strengths 
Strengths of this study include use of a ME/CFS specific symptom measurement tool that has 
strong psychometric properties and distinguishes between fatigue and PEM. It is known that 
a proportion of pwME have significant difficulties in accessing medical care or participating 
in research studies that require attendance at a facility (IOM, 2015). One potential benefit of 
online recruitment may be that some of these pwME may be able to participate in studies 
with a lower risk of exacerbating symptoms.  
5.5.2 Limitations  
The present study utilises correlation statistics that examines relationships between variables, 
however causation cannot be established. Further studies could examine the predictors of 
more severe fatigue, PEM and pain. Additionally, there are different dimensions to fatigue, 
such as cognitive fatigue (Karshikoff, Sundelin & Lasselin 2017), that may not be reflected 
using the DSQv1. Although the questionnaire includes a neurocognitive domain, it may 
require further validation with established fatigue questionnaires that examine different 
dimensions of fatigue such as the Fatigue Impact Scale (Fisk et al. 1994). 
Given the literature discussed in this thesis, it is plausible that increased PEM will result in 
reductions in everyday functional capacity. However, it may also be the case that the SF-36 is 
measuring an underlying level of severity, which may in turn effect how easily PEM is 
induced. Furthermore, we did not ask if participants were pacing to reduce symptoms hence it 
is not possible to assess the effect of activity management strategies on severity of symptoms 
or function hence speculation about the efficacy of pacing cannot be made. Although 
symptoms such as PEM and functional impairments such as reduction in physical function 
and low employment rates are consistent with other studies, we do not know if this is a 
representative sample of the full ME/CFS population in Australia. The influence of education 
and health literacy as factors in participating in online studies stands out as one further area 
of enquiry. Additionally, education and health literacy as mediators of severity of illness in 
ME/CFS warrants further investigation as there is a paucity of data on this. Future studies 
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could examine distinct groups such as lower socio-economic groups, ethnic minorities, 
Aboriginal and Torres Straight Islanders or the over 65 age group.  
5.5.3 Effect of co-morbidities 
Although the present study excluded those with a serious psychiatric diagnosis or head 
injury, comorbidities such as autoimmune disease or non-psychotic related mental health 
issues were not factored into the current analysis as mediators of severity of symptoms or 
everyday function and QoL. Several studies have shown co-morbidities in ME/CFS may 
influence symptom severity or functional impairment and impact on work status (Bateman et 
al. 2015; Natelson et al. 2019). As previously mentioned, a delay in diagnosis may mean that 
pwME are presenting with complications, which may include co-morbidities, that may alter 
symptom profiles and further reduce everyday functional capacity and QoL.  
5.6 Implications for research and practice  
5.6.1 Symptom research and care 
The NHMRC highlighted recently that there are no published referral pathways or guidelines 
to assist health care practitioners in appropriate management of ME/CFS within Australia 
(NHMRC, 2019). The present study highlights some of the symptoms that appear to have an  
impact on function and QoL for a group of pwME. This helps to inform health care 
practitioners on the symptoms to be particularly aware of when treating pwME. However, as 
can be seen from the DSQv1 symptom inventory, ME/CFS involves multiple symptoms 
hence it is important to understand the unique presentation and needs of each individual 
within the health care encounter. This could be achieved with an N of 1 study which may 
provide an avenue for examining the combined factors of living with a complex chronic 
illness such as symptom severity, functional capacity, structural supports, the lived 
environment and social connection. This may assist in understanding the factors that support 
and hinder access to healthcare (AIHW, 2018). The high severity rating of the symptom 
PEM, and the levels of everyday functional impairment in the present study suggests that the 
physical and cognitive resources required to access medical care may be impaired. A frequent 
theme in qualitative accounts is that pwME are seen on days they are well enough to be out 
visiting friends or attending medical appointments, however the consequent recovery time 
means they are at home and “invisible” at their worst times (Anderson, Jason & Hlavaty 
2014). Health care providers may not be seeing pwME on their worst days. Furthermore, 
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evaluation of the impact of accessing health care services should be considered given PEM 
may be triggered with minimal activity. There is limited literature on the practicalities of 
accessing healthcare for pwME. For instance, how do health care workers need to adjust care 
plans and expectations? Are there particular considerations for pwME regarding recovery 
from major or minor surgical procedures or other health care interventions such as dentistry 
or physiotherapy and what supports can be implemented to facilitate better recovery? One 
possible avenue to reduce the burden of accessing care may be better access to health care in 
the home. Telehealth and home visiting services are currently very limited in the Australian 
health care system. Telehealth in particular is often funded for people living in rural areas 
(AIHW, 2018). Although rural living may be a further factor limiting access to healthcare, it 
can be assumed that those who are too ill to leave the house will have problems accessing 
healthcare regardless of proximity to services.  
5.6.2 Economic and health service delivery implications 
The present study confirms previous literature on the low employment rates in a segment of 
the ME/CFS population in Australia. This suggests there is a potential economic 
disadvantage for this population with extended economic burden on caregivers, lost 
productivity and possibly higher health care utilisation; however there is a paucity of 
published data on these factors within the Australian health care context. For example, in 
addition to the problems with obtaining a diagnosis, the potential economic impact raises 
concerns regarding unmet health care needs outside of Medicare’s remit (physiotherapy, 
specialist services, non-Pharmaceutical Benefit Scheme medication). Are there food and 
housing security issues facing this population? Furthermore, potentially low rates of 
diagnosis may have implications for capturing health care service utilisation from large scale 
data sets such as hospital separation data although this may prove a useful starting point. The 
Australian Modification of the International Classification of Diseases (ICD-10-AM) is 
derived from the standardised classification system for epidemiology and health service 
utilisation maintained by the World Health Organisation (National Center for Health 
Statistics 2018). It is used in conjunction with Diagnostic Related Groups and the Australian 
Classification of Health Interventions to code all hospital separations and may provide one 
measure of health economic impact at the tertiary service delivery level.  
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5.7 Conclusion  
The literature review highlighted biological discoveries that demonstrate a multi-system 
process that particularly relates to problems with exertion and recovery from exertion 
resulting in the symptom construct of PEM. PEM is specific to ME/CFS and is associated 
with everyday functional limitations however generic fatigue scales are inadequate to 
measure this unique symptom construct. The SF-36 was identified as the most appropriate 
function and QoL assessment tool to use in the larger study the thesis draws from due to its 
discriminant capacity to distinguish between those with and without ME/CFS on a number of 
sub scales and due to the use of the tool to quantify significant reduction in function for the 
DSQv1. This study found a strong association between PEM, fatigue and pain and the PCS of 
the SF 36 and lends further support for the symptoms of PEM, fatigue and pain as factors in 
everyday functional limitations which has implications for targeting symptom management 
and treatment options. Although pain is not included as a required symptom for a diagnosis 
of ME/CFS according to the IOM criteria, this study supports the importance of exploring the 
existence of pain in pwME in a clinical context in order to reduce symptom burden. 
Furthermore, although prevalence of orthostatic symptoms and the autonomic symptom 
domain did not have a particularly high scores recent literature suggests a more global 
autonomic dysregulation in ME/CFS that may be reflected in the fatigue, PEM and pain 
domain scores. There remain questions regarding the suitability of some sub scales in the SF-
36 to capture meaningful variance in function. The floor effects in the Role Limitations due 
to physical problems and ceiling effects in Role Limitations due to emotional problems 
require further investigation. Furthermore, further validation of the DSQv1 in measuring 
different aspects of fatigue is warranted. The lack of clinical guidelines for ME/CFS in 
Australia are of particular concern given the high levels of everyday functional impairment 
identified in the present study and the health economic implications require further 
investigation in order to develop appropriate structural supports and for those living with 
ME/CFS in Australia.  
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(Pendergrast et 
al. 2016) 
C
ross 
section, 
quant 
using self 
report 
likert 
scales 
C
om
pare 
housebound vs 
non 
housebound 
 
SF 36 and 
D
SQ
 
25%
 housebound, 
sig  
Sig diff all except role 
phys, m
ental health and 
role em
otional. Lack of 
racial diversity 
B
ut sam
ples from
 4 
databases – heterogeneity 
across socio econom
ic 
(A
nderson, 
Jason &
 
H
lavaty 2014) 
Q
ualitative 
natural 
history 
Longitudin
al 
R
ecruited 
through 
epidem
iolo
gical 
sam
ple;  
Q
ualitative 
interview
s 
N
ested qual 
study using 
recall to 
exam
ine 
changes in life 
over tim
e due 
to M
E/C
FS 
Fukuda case definition. R
ecruited from
 a larger com
m
unity epi study w
ith 
physician diagnois and screening for exclusionary illness. G
ood population 
sam
ple w
ith spread of ethnicity, age, gender…
m
ore w
om
en represented 
Identified – occupational shift/reduction, global effect of stess (eg death of 
fam
ily m
em
ber, being a carer), fam
ily system
 changes, 
R
eductions in social and personal dom
ains by 1/3 group 
C
om
m
unity attitudes – in particular negative m
edical response  
Physical sym
ptom
ology – fatigue, PEM
, m
em
ory and concentration, sleep 
disturbance and pain; relapsing nature of the illness 
H
ealth changes – co m
orbid eg w
eight gain, auto im
m
une diagnosis, 
gender specific issues – M
E specific issues can w
oren w
hen com
bined 
w
ith other illnesses 
B
alancing activity as coping m
echanism
 
C
om
m
unity 
sam
ple 19 
people 
Illness experience e 
im
pacts across 
m
ultiple dom
ains eg 
fam
ily, w
ork, 
personal, m
ental, 
social 
Stress im
pacted on 
health, change in 
support structures 
Sm
all sam
ple 
H
elpful them
es identified 
Strength – part of a large 
epi sam
ple 
R
isk of recall bias 
  
  
79 
(Schafer et al. 
2015) 
C
ross 
section, 
quant – 
self report 
and 
actigraphy 
W
hich self 
report q’s 
reflect 
reduction in 
activity 
C
urrent w
ork activity highest association w
ith SF 36 scores 
A
ctigraphy, sf 
36, w
ork 
status, D
SQ
 
 
N
ot m
uch looks at 
quantifying this criteria 
for diagnosis 
(A
nderson et al. 
2012) 
M
eta 
synthesis 
of 
qualitative 
data 
To review
 and 
synthesize 
findings across 
qualitative 
studies on 
M
yalgic 
Encephalom
ye
litis/chronic 
fatigue 
syndrom
e 
(M
E/C
FS). 
First order constructs – experiences of people w
ith M
E/CFS – loss of 
identity, change in roles eg chidren taking on m
ore responsibility, p 4 
phases of illness and reconstruction of identity. Etiology – stress, infective,  
Q
ual lit supports the diagnostic criteria that describe substantial reductions 
across occupational, education, personal and or social dom
ains. “In 
particular, people w
ith M
E/ CFS describe social and econom
ic reductions, 
as w
ell as personal losses and disruptions, in addition to the physical 
reductions experienced in everyday life”p loss of social roles 
C
oping m
echanism
s – pacing, activity regulation,  
Sym
ptom
 descriptions -  
V
ictim
 blam
ing, psychosom
atic approach w
ith unclear biom
edical causes 
(p. 416) 
G
endered response 
W
oodw
ard, B
room
, and Legge [23] found that obtaining a diagnosis w
as 
the single m
ost helpful event in the search for social and m
edical 
legitim
acy during the course of their illness. P4 
 
 
 
Q
ual synthesis not as 
reducible as quant  
 V
arying diagnostic 
criteria  
 C
orrelates patient 
experiences w
ith data, 
helps to describe 
sym
ptom
s, identifies 
ethical and practical 
issues  
(K
ingdon et al. 
2018) 
com
pare 
the 
functional 
status and 
w
ell-being 
of people 
w
ith w
ell-
characteriz
ed 
M
E/C
FS 
w
ith 
people 
w
ith 
m
ultiple 
sclerosis 
(PW
M
S), 
as w
ell as 
W
hat is the 
difference in 
functional 
status and 
em
ploym
ent 
outcom
es 
betw
een 
M
E/C
FS, M
S 
and healthy 
controls 
W
ell characterised= 
 C
fs can be sim
ilar or in this cohort, m
ore disabling that M
S 
Low
er levels of em
ploym
ent m
aintenance – w
hat are the factors? Lack of 
treatm
ent, lack of support and understanding, level of functional im
pact 
higher? 
C
ross section 
U
K
 M
E/C
FS 
B
iobank to 
com
pare actual 
participant 
scores from
 the 
M
edical 
O
utcom
es 
Survey Short 
Form
-36 
v2TM
 (SF-
36v2TM
) 
betw
een 
groups 
People w
ith 
M
E/C
FS scored 
significantly low
er 
than PW
M
S or H
C
s 
in alm
ost all SF-
36v2 
furtherm
ore, 
em
ploym
ent and 
incom
e data are 
consistent w
ith loss 
of functional status. 
D
ifficult to generalize 
Self reported, som
e 
retrospective 
cross sectional design as 
m
ay not represent their 
illness on m
ore severe 
days 
  
  
80 
healthy 
controls 
(Jason, LA
 et al. 
2015) 
Factor 
analysis of 
D
SQ
 
U
nderlying 
factors to 
determ
ine 
groups or 
subtypes  
There m
ay be underlying groupings that m
ake m
ore sense that m
ay assist 
w
ith creating m
ore em
piric diagnostic criteria 
    
D
SQ
 and SF 
36 
six factor solution,  
Large num
bers but m
any 
self reported sym
ptom
s. 
U
se of validated self 
report m
easure, pain 
loaded across dom
ains so 
not counted as a discreet 
variable 
(H
ardcastle et 
al. 2016) 
System
atic 
review
 
C
om
pare 
various scales 
Severity scales m
ay assist w
ith distinguishing M
E/C
FS groups. N
ot 
uninform
 ally used so hard to com
pare studies 
 
 
Severity scales m
ay assist 
in identifying biological 
abnorm
alities.  
(Strassheim
 et 
al. 2017) 
Scoping 
literature 
review
 
Identify 
research 
relating to 
those severely 
and very 
severe 
C
ase studies reported that in extrem
e presentations very severe C
FS/M
E 
individuals m
ay be confined to bed, requiring reduced light and noise 
exposure. 
There are four categories of severity in the C
FS/M
E population: m
ild; 
m
oderate; severe; and very severe w
hich are expanded on elsew
here and 
adopted by the N
ational Institute for H
ealth and C
are Excellence  
N
arrative 
sum
m
ary of 
results as 
discussed 
Exam
ines a seldom
 
studied population 
 U
nable to do full 
system
atic given 
heterogeneity of literature 
(M
cM
anim
en et 
al. 2018) 
C
ross 
sectional, 
com
parativ
e, 
quantitativ
e 
R
isk factors 
for SI in 
M
E/C
FS 
U
nsupportive social interactions, severe sym
ptom
s, stigm
a, depression 
interact as risk factors for suicidal ideation 
D
SQ
, SF36, 
m
odified bec 
depression 
inventory, 
social stigm
a 
scale 
Sm
all percent w
ho 
have SI w
ithout 
depression 
Self report of sym
ptom
s 
First study to quantify 
these interactions 
(H
arvey et al. 
2008) 
Prospectiv
e birth 
cohort trial 
D
oes prior 
psychiatric 
illness 
predispose to 
M
E/C
FS 
 
Present state 
exam
ination, 
Pinter 
personality 
inventory, 
psychiatric 
sym
ptom
 
Y
es, prior 
psychiatric illness 
does predispose 
C
ontrolled for current 
depression, prospective 
birth cohort population 
study (rare!) but poorly 
defined M
E or C
FS at last 
m
easurem
ent so ? actually 
referring to M
E/CFS 
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frequency 
scale, various 
fatigue and 
fitness 
m
easures 
(Pheby &
 
Saffron 2009) 
O
bservatio
nal 
com
parativ
e study 
W
hat are the 
risk factors for 
severe 
M
E/C
FS 
 
B
arthel score 
for level of 
severity 
 
 
(M
ilrad et al. 
2017) 
C
ross 
section 
B
iological 
and self 
report data 
W
hat is the 
relationship 
betw
een 
subjective 
reports of poor 
sleep, fatigue 
and cytokines 
in w
om
en 
Poor sleep quality is associated w
ith severity of fatigue, pro inflam
m
atory 
cytokines 
W
orse sleep qual greater fatigue severity and greater assoc btw
 fatigue and 
every day tasks 
C
D
C
 C
FS, 
Pittsburg sleep 
qual index, 
fatigue 
sym
ptom
 
inventory, 
plasm
a 
M
ulti regression for 
associations 
D
oes not establish 
etiology of sleep problem
s 
Studies linking pathology 
and sym
ptom
s seem
 rare 
Supports  subjective 
reports of poor sleep 
quality w
ith evidence of 
inflam
m
ation and effects 
on areas of functioning 
(H
ayw
ood, 
Staniszew
ska &
 
C
hapm
an 2012) 
System
atic 
review
 of 
patient 
reported 
outcom
e 
m
easures 
 
C
ondition-specific, dom
ain-specific and generic m
ulti-item
 patient-
reported outcom
e m
easures (PR
O
M
s)  
Im
portance of capturing patient perspective of im
pact f health conditions 
R
eliability, 
validity, 
responsiveness 
 
B
efore D
SQ
 
SF36 only one w
ith 
reasonable evidence 
There is no published 
evidence of com
pletion 
rates, patient acceptability 
or feasibility of 
application for the 
rem
aining generic 
m
easures. Still floor 
effects. 
 
Interventions 
 
 
 
 
 
 
(C
ollatz et al. 
2016) 
System
atic 
review
 
Pharm
acologic
al 
interventions 
N
o universal pharm
a therapies can be recom
m
ended at this stage 
 
R
equire better 
studies on better 
defined cohorts to 
reach a conclusion 
System
atic review
 
(C
astro-M
arrero 
et al. 2017) 
Literature 
review
 
W
hat is the 
evidence for 
the different 
proposed 
therapies 
A
ppears com
prehensive, covers m
ajor areas of pharm
acological and non 
pharm
acological treatm
ent 
 
Evidence is 
w
eak, larger, 
better 
controlled 
Individual care for 
each situation, 
keeping in m
ind 
evidence levels and 
N
ot system
atic how
ever 
covers the m
ajor areas  
  
  
82 
trials required 
in m
any areas 
presentation of 
patient 
(B
row
n, 
K
horana &
 
Jason 2011) 
D
ata from
 
a larger 
longitudin
al study 
D
o patients 
w
ho start 
treatm
ent 
outside of their 
energy 
envelope 
im
prove in 
areas of 
fatigue, 
physical 
functioning, 
com
pared to 
those w
ho start 
and stay w
ithin 
that envelope 
D
em
onstrates tthat increased activity treatm
ents m
ay only be effective for 
a select group of patients 
 Those w
ho stayed w
ithin ee dem
onstrated im
provem
ents in fatigue and 
physical function 
 N
o support found for a universal increase in activity for all those w
ith 
M
E/C
FS 
 U
se of actigraphy data to have an objective elem
ent of m
easurem
ent apart 
from
 self-reported data These findings do not provide support for treatm
ent 
m
odels of M
E/C
FS w
hich suggest that increases in activity are necessary 
for patients w
ith M
E/CS to show
 im
provem
ent 
The Physical 
Functioning 
subscale sf-36 
H
ealth Survey 
The Fatigue 
Severity Scale 
(w
as used to 
assess fatigue 
severity. - 
those w
ho w
ere 
w
ithin their energy 
envelope before 
treatm
ent show
ed 
m
ore im
provem
ent 
in physical 
functioning and 
fatigue com
pared to 
those outside of 
their energy 
envelope.  
 
G
ET styled treatm
ent that 
pushes past sym
ptom
s not 
supported. Energy 
envelope m
ore useful 
 Large dropout as 
actigraphy identified as 
burdensom
e to collect for 
patients 
 Sm
all sam
ple size  
(Sunnquist &
 
Jason 2018) 
second-
stage 
conditional 
process 
m
odeling 
(i.e., 
m
oderated 
m
ediation) 
to re-
exam
ine 
the 
behavioura
l pathw
ay 
of the 
V
ercoulen 
et al. 
(1998) 
m
ode 
D
oes the 
V
ercoulen 
m
odel 
accurately 
represent those 
w
ith M
E/C
FS 
“This study represents the second attem
pt to replicate the V
ercoulen et al. 
(1998) m
odel; neither the Song and Jason (2005) nor the current study 
resulted in findings consistent w
ith the original m
odel. A
s this m
odel 
provides the theoretical foundation for cognitive behavioral and graded 
exercise treatm
ents for M
E and CFS, these failed replication attem
pts 
support patient-expressed concerns about the appropriateness and efficacy 
of these treatm
ents.” 
 
indicated that 
individuals did not 
reduce their activity 
level due to illness 
beliefs. A
lthough 
activity level and 
im
pairm
ent w
ere 
significantly 
correlated, this 
correlation 
decreased as case 
definition 
stringency increased 
M
asters dissertation but 
published and peer 
review
ed 
(Sharpe et al. 
2015) 
Follow
 up 
investigate 
long-term
 
outcom
es (at 
least 2 years 
after 
random
ization) 
U
se of oxford criteria 
 
There w
as little 
evidence of 
differences in 
outcom
es betw
een 
the random
ised 
A
uthors m
aintain 
im
provem
ent  - although 
concede m
uddied by 
inclusion and lack of 
control over other 
additional therapies 
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originally 
included in the 
PA
C
E trial. 
treatm
ent groups at 
long-term
 follow
-up 
included over the long 
term
 
(Jason, L. et al. 
2009) 
C
om
pariso
n betw
een 
those 
m
aintainin
g their ee 
and those 
outside of 
ee 
D
oes 
m
aintaining 
activity w
ithin 
the EE 
im
prove 
function over 
tim
e 
D
escribes a num
ber of scales  - fatigue severity scale and short form
 36 
Interesting discussion of theories w
hy extending beyond envelope causes 
an increase in sym
ptom
s 
 
Staying w
ithin EE 
dem
onstrated 
im
proved function 
in physical function 
and  fatigue severity   
Sm
all sam
ple size  
(G
oudsm
it et al. 
2012) 
C
ritical 
review
 
Pacing 
strategies 
Pacing consistently identified as the preferred sym
ptom
 m
anagem
ent 
strategy am
ongst patients 
 
Sim
ilar to above, 
num
ber of studies 
have found pacing 
can reduce PEM
 
C
ritical evaluation of pros 
and cons, strengths and 
w
eaknesses 
(Fluge et al. 
2019) 
R
andom
ise
d controlled 
trial 
B
 lym
phocyte 
depletion w
ith 
rituxim
ab – 
does it help 
C
anadian C
onsensus C
riteria cohort 
R
epeated 
m
easures 
fatigue scores, 
SF 36, adverse 
events, 
physical 
activity level 
B
oth prim
ary and 
secondary end 
points not achieved, 
in contrast to 
previous open label 
studies 
R
C
T, very rare in this 
population 
D
iagnostic 
criteria 
 
 
 
‘ 
 
 
(B
rurberg et al. 
2014) 
System
atic 
review
 
C
ase 
definitions, 
w
hat 
populations are 
they 
representing 
The prevalence estim
ates based on self-reports show
ed high variability, 
w
hile clinically assessed estim
ates w
ere m
ore consistent, especially in the 
com
m
unity sam
ples.  
 
 
Sensitivity and 
specificity is an 
issue for A
LL 
criteria. Even m
ore 
selective criteria 
m
ay at tim
es 
include 
psychopathology 
System
atic, in depth 
analysis of criteria 
 (C
arruthers et 
al. 2003) 
Expert 
consensus 
C
ase definition 
R
equires PEM
, C
anadian C
onsensus C
riteria 
 
Expert consensus 
For clinical application, 
not em
pirically tested 
(Jason et al. 
2012) 
C
om
parati
ve, cross 
section, 
quant 
C
ontrasting 
case 
definitions 
R
am
sey and C
C
C
 appear to select a m
ore severely im
pacted subset of 
patients com
pared to the Fukuda critiera 
Prequel to 
D
SQ
 for 
sym
ptom
s, SF 
36, psychiatric 
interview
, 
m
edical 
H
igher hr in M
E 
and M
E/C
FS vs 
Fukuda, longer 
trailm
aking tim
es in 
M
E/C
FS and M
E vs 
Fukuda (cog test) 
M
edical diagnosis , 
excluded the very sick ie 
housebound or w
heelchair 
bound 
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assessm
ent – 
cog testing and 
heart rate 
m
onitoring 
(C
arruthers et 
al. 2011) 
Expert 
consensus 
statem
ent 
To provide an 
agreed upon, 
specific to M
E 
set of 
diagnostic 
criteria for 
both adults and 
paediatrics 
To provide an agreed upon, specific to M
E set of diagnostic criteria for 
both adults and paediatrics  
Post exertional, neuroim
m
une exhaustion cardinal sym
ptom
 and essential 
to a diagnosis 
Pain and fatigue are bio alarm
 signals and m
ust be treated seriously, they 
are a part of a global protection response 
 
 
Expert consensus 
R
em
oved fatigue and six 
m
onth requirem
ent, m
uch 
m
ore com
plex,  
(Institute of 
M
edicine (IO
M
) 
2015) 
M
ajor 
review
 of 
evidence 
and 
proposal of 
alternate 
criteria 
 
Paradigm
 changing, em
phasis on biological basis for M
E/C
FS 
N
ew
 criteria does not include Pain or The SEID
 criteria leave sym
ptom
s 
such as pain, im
m
unological m
anifestations such as raised lym
ph nodes or 
sore throat or gastrointestinal sym
ptom
s out of the diagnostic process 
entirely 
Literature 
review
, 
system
atic 
review
,  
For easier clinical 
identification, now
 
used on C
D
C
 
w
ebsite as criteria 
Som
e criticism
 of the 
criteria in the literature ie 
(Jason, Leonard, 
M
cM
anim
en, Stephanie, 
et al. 2015). SEID
 not as 
selective, broader range of 
severity captured than 
som
e, but m
ore selective 
than Fukuda.  
E
pidem
iology  
 
 
 
 
 
 
(B
araniuk 2017) 
Population 
prevalence 
btw
 C
D
C
 
and 
O
xford 
To com
pare 
the selectivity 
of O
xford and 
Fukuda criteria 
in a U
.S. 
population 
O
xford criteria low
 threshold not particularly specific 
 
V
ery little overlap 
betw
een criteria, 
O
xford very broad 
 
(Johnston et al. 
2013) 
M
eta 
analysis 
M
eta analysis 
to look at 
differences in 
prevalence 
according to 
m
ethod of 
assessm
ent 
used  
H
eterogeneity of prevalence m
ay in part be due to the variations in 
m
ethods of assessm
ent, in particular betw
een self report and clinical 
assessm
ent 
H
elpful discussion p108 on gathering data, estim
ating prevalence and tools 
used 
C
D
C
 criteria 
(Fukuda) 
A
dults – self 
reporting vs 
clinical 
assessm
ent 
H
igh variability 
w
ith self reported 
M
ore consistency 
w
ith clinical 
reported. 
Pooled prev 0.87 
IC
C
 had not been out long 
– Fukuda m
ost reliable for 
this study tim
efram
e 
U
se of Fukuda – low
er or 
higher possible depending 
on criteria and place of 
sam
pling 
(R
eeves et al. 
2007) 
Epidem
iol
ogy 
To sam
ple 
G
eorgian 
population for 
C
FS 
 
R
andom
 digit 
dialling to 
sam
ple 
population 
Prevalence 2.54%
, 
used C
D
C
 criteria, 
higher prevalence 
than other studies 
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m
etro, urban 
rural G
eorgia, 
Follow
 up 
psych and 
m
edical  
(Jason et al. 
1999) 
Eidem
iolo
gy, 
com
m
unit
y 
To sam
ple the 
greater 
C
hicago area 
for a 
com
m
unity 
based sam
ple 
establish 
prevalence 
“There w
ere no significant differences betw
een in- 
individuals w
ith C
FS and controls w
ith respect to m
arital 
status, educational attainm
ent, or occupational status. 
H
ow
ever, individuals w
ith CFS differed significantly from
 
controls w
ith respect to current em
ploym
ent status.”p2136 
 
R
andom
 digit 
dialling, follow
 
up w
ith psych 
and m
edical 
greater 
C
hicago area 
Prevalence 0.43%
 
m
ore selective ,but 
consistent w
ith 
R
eeves that 
disproportionate 
w
om
en, ethnic 
m
inority, low
er edu 
and oc status 
R
ealatively sm
all sam
ple 
size for epi – N
=1031 
B
iological 
 
 
 
 
 
 
(D
aniel, 
A
nnesley &
 
Fisher 2019) 
R
eview
 
article 
 
D
espite these challenges, m
odern research dem
onstrates a tangible 
biom
edical basis for the disorder across m
any body system
s. This evidence 
is m
ostly com
prised of disturbances to im
m
unological and inflam
m
atory 
pathw
ays, autonom
ic and neurological dysfunction, abnorm
alities in 
m
uscle and m
itochondrial function, shifts in m
etabolism
, and gut 
physiology or gut m
icrobiota disturbances.  
H
om
eostatic shift 
D
raw
ing from
 
and critically 
review
ing 
biological 
evidence in 
different areas 
 
R
eview
 article, not 
system
atic 
(van C
am
pen &
 
V
isser 2018) 
 
 
D
ecreases in stroke volum
e and cardiac output are not significantly 
different betw
een m
ild, m
oderate, and severe M
E/C
FS patients. Therefore, 
this suggests that deconditioning does not explain the larger decrease in 
stroke volum
es and cardiac output in M
E/C
FS patients com
pared to 
healthy controls.  
 
 
R
em
oved those w
ith 
PO
TS or know
n 
orthostatic 
intolerance  - ie 
included pts w
ith 
otherw
ise norm
al 
ttt, diagnosis. 
D
oppler carotid 
artery 
Stroke volum
e index sig 
low
er in M
E/C
FS on tilt 
but no sig changes w
ithin 
group stratified by 
severity 
C
ardiac output low
er 
?reduced blood volum
e, 
reduced sym
p/parasym
p 
tone ?dys reg autonom
ic 
nervous system
 
N
ursing 
 
 
 
 
 
 
(R
yckeghem
 et 
al. 2017) 
Q
ual 
interview
s 
Explore 
experience and 
expectations of 
G
P’s and 
patients for 
role of nurse 
practitioners 
D
eficiencies in guidance for patients 
“C
oordinating care and tim
ely com
m
unication w
ith all relevant health 
care- givers and the patient is im
portant. This study show
ed that G
Ps can 
only partially fulfil this coordinating role, partly because of difficulties in 
com
m
unication betw
een the G
P and the referral centre “ 
 
Sem
i 
structured 
interview
s 
C
entral role of a 
specialist nurse in 
coordinating care of 
a m
ultidisciplinary 
approach to care 
and treatm
ent 
R
are nursing article that 
asked patients and G
P’s 
w
hat w
ould help them
. 
A
us context m
ay look 
different 
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(C
hew
-G
raham
 
et al. 2011) 
N
ested 
qual study 
in larger 
random
ize
d PA
C
E 
trial 
Factors 
influencing 
participation in 
a nurse led 
hom
e therapy 
of G
ET and 
C
B
T 
Patient beliefs tow
ards foundation of treatm
ent influence engagem
ent ie 
m
odel of illness m
akes a difference 
H
igh tensions w
hen nurse and patient disagree 
 
C
onclude that G
P’s 
need to screen 
patients for 
underlying beliefs 
regarding sym
ptom
s 
before referring to 
such a service  
M
odel based on “false 
illness beliefs” 
Som
e patients did find 
validation in not being 
alone w
ith experience of 
sym
ptom
s. Tension in 
nurse/patient relationship 
w
hen disagreem
ent on 
causes of sym
ptom
s 
 
  
 
 
87 
Appendix 2 SF-36 and WHOQOL evaluation 
ME/CFS specific studies 
 WHOQOL SF -36 
Quality of life in patients with CFS (Van Heck & 
De Vries 2002) 
Yes, WHOQOLl 
100 – not short 
form  
 
Expecting a good quality of life in health: assessing 
people with diverse diseases and conditions using 
the WHOQOL‐BREF (Skevington & McCrate 
2012) 
WHOQOL-BREF 
discriminant 
validity.Compared 
with the SF‐36, 
WHOQOL 
physical and 
psychological 
domains showed 
good concurrent 
validity, although 
social was weak.    
 
A comparison of health status in patients meeting 
alternative definitions for chronic fatigue 
syndrome/myalgic encephalomyelitis  (Johnston et 
al. 2014) 
WHO DAS 
Not directly 
compared but 
appear to 
corroborate 
eachother – ICC 
worse scores in all 
WHODAS 
domains compared 
to Fukuda 
Yes – Australian based study – community 
based sample. ICC lower scores in all 
domains compared to Fukuda. 
 
Assessment of activity limitations and participation 
restrictions with persons with chronic fatigue 
syndrome: a systematic review (Vergauwen et al. 
2015) 
WHOQOL 100 – 
can distinguish 
btw healthy 
controls and CFS 
 
A national cross-sectional survey of diagnosed 
sufferers of myalgic encephalomyelitis/chronic 
fatigue syndrome: pathways to diagnosis, changes in 
quality of life and service priorities (Comiskey & 
Larkan 2010) 
WHOQOl- bref 
Cross section, 
delays in 
diagnosis, need for 
QOL, mean delay 
in diagnosis 4.7 
years. Responsive 
to changes pre and 
post illness - 
retrospective 
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Are Myalgic Encephalomyelitis and chronic fatigue 
syndrome different illnesses? A preliminary analysis 
(Jason et al. 2016)  
 sf-36 to measure levels of impairment 
across different diagnostic criteria – as 
identified by the DSQ -differences in 
severity depending on criteria so useful for 
breaking down types and areas of severity  
 
Functional status in patients with CFS and other 
fatiguing illnesses and healthy controls 
(Buchwald et al. 1996) 
 Strongest correlation between physical 
functioning, role functioning, general health 
and body pain with CDC listed symptoms 
of flulike illness, fever, chills, sore throat, 
painful lymph nodes, weakness and 
myalgia. Emotional, social, mental health 
and vitality correlated poorly with signs and 
symptoms 
Contrasting Chronic Fatigue Syndrome verses 
Myalgic Encephalomyelitis/Chronic Fatigue 
Syndrome (Jason et al. 2013)  
 SF-36 can help distinguish between CFS 
and other illnesses but not within the 
different CFS constructs – older study 
without newer specific criteria 
Integration of DNA methylation & health scores 
identifies subtypes in myalgic 
encephalomyelitis/chronic fatigue syndrome (de 
Vega et al. 2018)  
 Use De Paul and SF-36 to examine severity 
of symptoms, the SF-36 was an important 
component of correlating different subsets 
as identified by the DSQ into severity 
categories  
Measuring substantial reductions in Functioning in 
patients with CFS (Jason et al. 2011) 
 Mental health component poor discriminant 
ability. Vitality, social functioning and Role 
Physical best discriminant ability. also 
evaluated past studies using controls and 
found that these three subscales still held . 
Davenport 2011 diverges with mental 
health having some predictive power for 
recovery fromPEM. Contains summary 
table of different SF36 results for a number 
of studies that report all 8 domains 
Measuring substantial reductions in activity 
(Schafer et al. 2015) 
 Comparing current and past occupational 
status strong determinant of reduction in 
function. Correlation matrix: pos corr btw 
past occ and physical funct, vitality, and 
social funct. Current work pos with 
physical funct, bodily pain, vitality. Current 
household activities pos ass physical funct, 
role physical, vitality and social 
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Health Status in Patients with Chronic Fatigue 
Syndrome, General Population and Disease 
Comparison Groups (Komaroff et al. 1996) 
 Strong correlations with fevers, pharyngitis, 
muscle weakness, PEM and difficult 
thinking across the physical functioning 
domains – although R is not directly 
reported but the statistical significance 
p288. Use of older Holmes minor criteria.  
Pain is associated with reduced quality of life and 
functional status in patients with Myalgic 
Encephalomyelitis and Chronic Fatigue Syndrome 
(Strand et al. 2019) 
 deficits on the physical functioning, bodily 
pain, general health functioning and social 
functional scales  
 
The utility of patient reported outcome measures in 
people with Myalgic Encephalomyelitis/Chronic 
Fatigue Syndrome (Murdock et al. 2017) 
 Scores were reversed…but equal to floor 
effects found in role physical had 
?consistency and floor effects problems 
Functional Status and Well-Being in People with 
Myalgic Encephalomyelitis/Chronic Fatigue 
Syndrome Compared with People with Multiple 
Sclerosis and Healthy Controls (Kingdon et al. 
2018) 
 Yes – good comparison data -MS and 
ME/CFS participants from a UK biobank. 
Group comparisons, not broken down by 
symptoms. Reports 8 domains.  
Reliability and validity of Short Form 36 Version 2 
to measure health perceptions in a sub-group of 
individuals with fatigue (Davenport et al 2011) 
 High concurrent validity sf36 and MIF 20 
Floor effect in phys funct, role phys, 
vitality, mental health, social function, 
general health 
 
 
 
 
Comparative study: 
Measuring health-related quality of life in adults with chronic conditions in primary 
care settings (Hand 2016) 
Quote: "The abbreviated World Health Organization Quality of Life Scale (WHOQOL-
BREF), the 36-Item Short Form Health Survey (SF-36), and the Duke Health Profile were 
critiqued. All address physical, mental, and social domains, while the WHOQOL-BREF also 
addresses environment. Psychometric evidence supports use of the SF-36 and WHOQOL-
BREF with this population. The SF-36 has the most evidence of responsiveness but has some 
floor and ceiling effects, while the WHOQOL-BREF does not appear to have floor or ceiling 
effects but has limited evidence of responsiveness. The WHOQOL-BREF has the highest 
proportion of individualized items which is a consideration in terms of burden on 
respondents.” 
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SF-12 
Acupuncture for chronic fatigue syndrome: a randomized, sham-controlled trial with single-
blinded design (Ng & Yiu 2013). Only reference to SF-12. SF 12 requires more research in 
ME/CFS population before using as measurement of reduction in function.
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Appendix 3 Study flyer 
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Appendix 4 Screening questionnaire 
 
Age: _______ (if aged under 18 years or over 65 years, individual is excluded) 
Are you able to read and speak English?  Y    /    N (if no, individual is excluded) 
Do you have any uncorrected visual difficulties?     Y   /   N 
 If yes, provide details? 
_______________________________________________________ 
 
(Researcher to make decision about whether visual difficulties would prevent 
individual from validly completing tasks) 
Do you have a diagnosis of a psychotic, bipolar or related disorder? ______________ 
Do you have a history of brain injury or other neurological illness? ______________ 
Do you have a history of alcohol or illicit drug abuse? ______________  
Are you pregnant? __________________ 
 (if yes to any of the above questions, individual is excluded) 
Is your CFS diagnosis verifiable by a suitably qualified medical practitioner? 
___________________________ 
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Appendix 5 Participant Information 
 
 
 
 
 
Discipline of Psychology, School of Medicine University of Tasmania   
   
Participant Information Sheet   
Fatigue in Multiple Sclerosis/Chronic Fatigue Syndrome    
Introduction   
You are invited to participate in a study that examines the nature of fatigue, factors that influence 
fatigue and how fatigue affects functional everyday outcomes. The research is being conducted by Dr 
Cynthia Honan and Dr Jane O’Brien. Ms Kate Donnelly will be assisting with the study in partial 
completion of an Honours in Nursing degree.   
Purpose of the study   
The purpose of this study is to investigate the relationship between subjectively experienced fatigue 
and functional outcomes (e.g., everyday social functioning, social participation, employment, quality 
of life) in people with multiple sclerosis (MS)/chronic fatigue syndrome (CFS) when compared to 
healthy individuals. Factors that may influence this relationship including sleep, illness severity, 
social support, diet and lifestyle, and cognitive skills, will also be investigated.   
What does my participation involve?   
If you wish to take part in this study, you will be asked some initial screening questions aimed at 
identifying whether you are suitable to participate. If you are deemed suitable, you will be emailed a 
unique participant number and a weblink to complete the full survey online. The survey will contain a 
series of questionnaires related to your: (1) general background; (2) MS/CFS symptoms (if you have 
MS/CFS); (3) diet; (4) alcohol use; (5) symptoms of depression; (6) experience of fatigue; (7) 
experience of daytime sleepiness; (8) sleep quality; (9) perceived thinking difficulties; (10) social 
functioning; (11) social support; and (12) quality of life and social participation. It is recommended 
that completion of the survey in the one sitting, although breaks can be taken when required. It is 
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estimated that the survey will take 40 to 70 minutes to complete. If you feel that you would like to 
complete the survey over a longer period of time, we can post the survey to you.   
We will also ask you for permission to contact a family member or friend to complete a short survey 
about your social functioning and integration as a result of your illness or condition. A link will be 
provided at the end of the survey which can be emailed directly to your family or friend for 
completion.   
Risks   
There is minimal risk associated with your participation in this study. You may start to feel tired or 
fatigued while completing the questionnaires. Should this fatigue become excessive and you do not 
wish to continue, please advise the researcher and/or speak with your regular doctor about 
your fatigue. The questionnaires in this study also have the potential to cause distress due to their 
personal content relating to relationships with partners and family. If you are concerned about these 
questions and/or do feel distressed, please contact your regular doctor, Lifeline on 13 11 14 or MS 
Australia on 1800 042 138, or the researchers on 03 6324 3266.   
Benefits   
The current research is intended to improve our understanding of the nature of fatigue and the link 
that fatigue may have with various functional outcomes in MS/CFS. Whilst the benefits of 
participating in this research may not be of direct benefit to you, your participation will provide us 
with some invaluable information that will assist other people with MS/CFS, researchers, and 
clinicians to further understand in particular the types of fatigue-related factors which are most 
relevant in predicting everyday functioning. Such an understanding is important as it may lead to 
more effective rehabilitative treatment programs for those who experience difficulties with fatigue.   
Note that your individual results from the questionnaires will not be available.   
Recompense to Participants   
There will be no payment to individuals who participate in this study.   
Consent   
You are encouraged to discuss your participation with a family member, carer, or doctor prior to 
consenting to participate in this research. Where possible (or if asked by the researchers), please have 
a family member or carer present to witness your consent prior to completing the survey. 
Acknowledgement of the presence of a witness can be provided in the online survey link or by having 
your witness co-sign the included consent form (if receiving a hard-copy of the survey in the mail).   
Voluntary ParticipationParticipation in this study is entirely voluntary. You do not have to take part in 
it. If you do take part, you can withdraw at any time without having to give a reason. Whatever your 
decision, please be assured that it will not affect your relationship with the researchers or any other 
medical personnel. Only the researchers named above will be aware of your participation or non-
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participation. We recommend that you have a family member or friend present when agreeing to 
participate in this study.    
Confidentiality   
All the information collected from you for the study including all medical history and results will be 
treated confidentially, and only the researchers named above will have access to it. The results of this 
study may be presented at a conference or in a scientific publication, but individual participants will 
not be identifiable.   
Further Information   
When you have read this information, the researchers will be available to discuss it with you further 
and answer any questions you may have. If you would like to know more at any stage, please feel free 
to contact Kate Donnelly on kated@utas.edu.au or Dr Honan on cynthia.honan@utas.edu.au.    
How do I find out the results of the study?   
Results of the overall study can also be obtained by contacting Dr Honan on 03 6324 3266 
or cynthia.honan@utas.edu.au.   
Ethics Approval and Complaints   
This study has been approved by the Tasmanian Health and Medical Human Research Ethics 
Committee. If you have concerns or complaints about the conduct of this study should contact the 
Executive Officer of the HREC (Tasmania) Network on (03) 6226 7479 or 
email human.ethics@utas.edu.au. The Executive Officer is the person nominated to receive 
complaints from research participants. You will need to quote H0015630. Any complaint you make 
will be treated in confidence and investigated.   
Who do I contact if I wish to speak to someone about my mental health?   
As aforementioned, a number of questions will be asked about psychological functioning and alcohol 
and other drug use. Whilst it is not anticipated that these questionnaires will cause distress, please do 
not hesitate to let the researcher know. If you are concerned about your mental health please contact 
your regular doctor, Lifeline on 13 11 14 or MS Australia on 1800 042 138, or the researchers.   
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Appendix 6 Consent form 
 
 
 
 
Discipline of Psychology, School of Medicine University of Tasmania    
PARTICIPANT CONSENT FORM   
Fatigue in multiple sclerosis/chronic fatigue syndrome   
I acknowledge that the nature, purpose and contemplated effects of the project so far as it affects me, 
have been fully explained to my satisfaction by the research worker and my consent is given 
voluntarily.   
The details of the procedure proposed have also been explained to me, including the anticipated 
length of time it will take, the frequency with which the procedure will be performed, and an 
indication of any discomfort, which may be expected.  I understand that my involvement means 
completing a survey (estimated time 40-70 min), although this may be longer if breaks are included.   
I understand that there are the following risks or discomfort: fatigue due to questionnaire completion, 
and possible distress due to personal questioning about relationships.   
Although I understand that the purpose of this study is to improve our understanding of fatigue in 
MS/chronic fatigue syndrome, leading to improved rehabilitation and treatment, it has also been 
explained that my involvement may not be of any benefit to me and that I will not be able to obtain 
my individual results from the researchers.   
I have been notified that it is best to have a member of my family or a friend present while consenting 
to participate in this study.   
I am informed that no information regarding any medical history will be divulged and the results of 
any tests involving me will not be published so as to reveal my identity.   
I understand that my involvement in the project will not affect my relationship with the researchers or 
the University of Tasmania. I also understand that I am free to withdraw from the study at any time 
and have my data not be included in the study.    
I understand that in agreeing to this electronic consent form, I am consenting to participate in the 
study. I am not giving up my legal right by agreeing to this consent form.   
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I understand that the trial will be conducted in accordance with the latest versions of the National 
Statement on Ethical Conduct in Human Research 2007 and applicable privacy laws.   
   
I acknowledge that I have read the participant information sheet, have completed the screening 
questions, and   
are deemed eligible to participate.   Yes/No   
I agree to participate in this study.   
Yes/No/Unsure (I would like to be contacted to discuss this 
further)   
       IF Unsure, please enter your contact details (phone or email)   
       ______________________   
Please enter your participant number to begin: ______________________   
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Appendix 7 Demographics  
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Appendix 8 DePaul Symptom Questionnaire 54 symptom section 
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Appendix 9 Medical Outcomes Short Form 36 
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Appendix 10 Email templates 
Email to indicate eligibility and allocate participant number: 
Thank you for expressing your interest in participating in the Impact of Fatigue in CFS 
(Myalgic Encephalomyelitis): Symptoms and Outcomes Study and for completing the 
screening questionnaire. Your responses indicate that you are eligible to participate in this 
study. 
  
Your participant number is: 1234 
  
You will need this number to enter the survey. 
  
Please click on the following link to read the full participant information sheet, complete the 
consent form and complete the questionnaire. This questionnaire should take between 40 and 
70 minutes to complete. If you wish to take a break, you can close the survey and return via 
this link. https://www.surveymonkey.com/r/VF73779 
 
There is also a brief 5-to-10 minute questionnaire that we are hoping someone who 
knows you well can complete. This forms part of our extended investigation of how fatigue 
may affect social functioning. Participation in this is 
optional.www.surveymonkey.com/r/FBHCMLP 
 
Impact of Fatigue in Chronic Fatigue 
Syndrome (Myalgic 
Encephalomyelitis) (Symptoms and 
Outcomes Study) Informant 
Questionnaire 
www.surveymonkey.com 
 111 
Take this survey powered by surveymonkey.com. 
Create your own surveys for free. 
Many thanks for participating in this study. Your participation is invaluable to us and very 
much appreciated. If you have any questions or concerns, please do not hesitate to contact me 
on 0437468758 or kated@utas.edu.au. You can also contact the principal investigator Dr 
Cynthia Honan on 03 6324 3266 or cynthia.honan@utas.edu.au. 
Kind regards, 
Kate Donnelly, RN 
Honours in Nursing candidate 
Nursing | School of Health Sciences 
College of Health and Medicine 
University of Tasmania 
Tel: +61 (0)4 .... .... 
Email: kated@utas.edu.au 
utas.edu.au/health 
Email to indicate not eligible 
Dear 
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Thank you for expressing your interest in participating in the Impact of Fatigue in CFS 
(Myalgic Encephalomyelitis): Symptoms and Outcomes Study and completing the screening 
questionnaire. 
Your responses indicate that you are not eligible to participate in this study. In particular, you 
have indicated that you ……….. 
We appreciate that you have taken the time to undertake the screening process and should we 
undertake further studies, we would welcome your interest in participation. Please do not 
hesitate to email me if you would like to discuss this further. 
You can also contact the principal investigator Dr Cynthia Honan on 03 6324 3266 
orcynthia.honan@utas.edu.au. 
Kind regards 
Kate Donnelly, RN 
Honours in Nursing candidate 
Nursing | School of Health Sciences 
College of Health and Medicine 
University of Tasmania 
Tel: +61 (0)4 .... ....
Email: kated@utas.edu.au 
utas.edu.au/health 
Reminder email: 
Dear 
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A short time ago you indicated your interest in completing our survey ‘Impact of Fatigue in 
Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): Symptoms and Outcomes Study. 
This important study aims to expand our current understanding of the manner in which 
CFS/ME might affect every day functioning. We would still very much value your input into 
this study if you are able to spare the time. You can enter the survey via the link in the 
original email. 
Kind regards, 
Kate Donnelly, RN 
Honours in Nursing candidate 
Nursing | School of Health Sciences 
College of Health and Medicine 
University of Tasmania 
Tel: +61 (0)4 .... .... 
Email: kated@utas.edu.au 
utas.edu.au/health 
Thankyou emial for completed surveys: 
Dear 
We wish to thank you for completing the surey by the University of Tasmania Impact of 
Fatigue in Chronic Fatigue Syndrome (Myalgic Encephalomyelitis): Symptoms and 
Outcomes Study.  
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The research is intended to improve our understanding of CFS/ME Symptomology and the 
link this may have with everyday functional outcomes in CFS/ME. Your participation will 
provide us with some invaluable information that will assist other people with CFS/ME, 
researhcers, clinicians in the future. 
Your participation is invaluable to us and very much appreciated. If you have any questions 
or concerns, plese do not hesitate to contact me on 0437468758 or kated@utas.edu.au. You 
can also contact the principle investigator Dr Cynthia Honan on 03 243266 or 
cynthia.honan@utas.edu.au 
Kind regards 
Kate Donnelly, RN 
Honours in Nursing candidate 
Nursing | School of Health Sciences 
College of Health and Medicine 
University of Tasmania 
Tel: +61 (0)4 .... .... 
Email: kated@utas.edu.au 
utas.edu.au/health 
